<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Diagnostics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Diagnostics (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2841</journal-id><journal-id journal-id-type="pmc-domain">diagno</journal-id><journal-id journal-id-type="publisher-id">diagnostics</journal-id><journal-title-group><journal-title>Diagnostics</journal-title></journal-title-group><issn pub-type="epub">2075-4418</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10572558</article-id><article-id pub-id-type="pmcid-ver">PMC10572558.1</article-id><article-id pub-id-type="pmcaid">10572558</article-id><article-id pub-id-type="pmcaiid">10572558</article-id><article-id pub-id-type="pmid">37835874</article-id><article-id pub-id-type="doi">10.3390/diagnostics13193132</article-id><article-id pub-id-type="publisher-id">diagnostics-13-03132</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension&#8212;A Challenging Mystery</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3808-7047</contrib-id><name name-style="western"><surname>Kacprzak</surname><given-names initials="A">Aneta</given-names></name><xref rid="c1-diagnostics-13-03132" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tomkowski</surname><given-names initials="W">Witold</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Szturmowicz</surname><given-names initials="M">Monika</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Tsangaris</surname><given-names initials="I">Iraklis</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-diagnostics-13-03132">1st Department of Lung Diseases, National Tuberculosis and Lung Diseases Institute, Plocka 26, 01-138 Warsaw, Poland</aff><author-notes><corresp id="c1-diagnostics-13-03132"><label>*</label>Correspondence: <email>ankac2000@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2023</year></pub-date><volume>13</volume><issue>19</issue><issue-id pub-id-type="pmc-issue-id">447273</issue-id><elocation-id>3132</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2023</year></date><date date-type="rev-recd"><day>27</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>14</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-25 22:25:10.870"><day>25</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="diagnostics-13-03132.pdf"/><abstract><p>Sarcoidosis has been a well-recognised risk factor for pulmonary hypertension (PH) for a long time, but still, the knowledge about this concatenation is incomplete. Sarcoidosis-associated PH (SAPH) is an uncommon but serious complication associated with increased morbidity and mortality among sarcoidosis patients. The real epidemiology of SAPH remains unknown, and its pathomechanisms are not fully explained. Sarcoidosis is a heterogeneous and dynamic condition, and SAPH pathogenesis is believed to be multifactorial. The main roles in SAPH development play: parenchymal lung disease with the destruction of pulmonary vessels, the extrinsic compression of pulmonary vessels by conglomerate masses, lymphadenopathy or fibrosing mediastinitis, pulmonary vasculopathy, LV dysfunction, and portal hypertension. Recently, it has been recommended to individually tailor SAPH management according to the predominant pathomechanism, i.e., SAPH phenotype. Unfortunately, SAPH phenotyping is not a straightforward process. First, there are gaps in our understanding of undergoing processes. Second, the assessment of such a pivotal element as pulmonary vasculature on a microscopic level is non-feasible in SAPH patients antemortem. Finally, SAPH is a dynamic condition, multiple phenotypes usually coexist, and patients can switch between phenotypes during the course of sarcoidosis. In this article, we summarise the basic knowledge of SAPH, describe SAPH phenotypes, and highlight some practical problems related to SAPH phenotyping.</p></abstract><kwd-group><kwd>sarcoidosis</kwd><kwd>pulmonary hypertension</kwd><kwd>phenotypes</kwd><kwd>treatment</kwd></kwd-group><funding-group><funding-statement>This research did not receive any funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-diagnostics-13-03132"><title>1. Introduction</title><p>Pulmonary hypertension (PH) is a haemodynamic state of elevated blood pressure in the pulmonary artery shared by many conditions, and right heart catheterisation (RHC) remains the gold standard for its diagnosis [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>]. For decades, 25 mmHg was the cut-off value for increased mean pulmonary arterial pressure (mPAP) at rest. Only recently, resting PH has been redefined as mPAP &gt; 20 mmHg, and exercise PH was re-introduced with a new definition [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>]. The haemodynamic categories of PH are presented in <xref rid="diagnostics-13-03132-t001" ref-type="table">Table 1</xref>.</p><p>Another commonly used PH classification is the World Health Organisation&#8217;s (WHO) clinical classification. It consists of five main PH groups in which clinical conditions associated with PH are categorised on the basis of similar PH pathophysiological mechanisms, clinical presentation, haemodynamic characteristics, and management [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>].</p><p>Sarcoidosis has been long recognised as a risk factor for PH. First, sarcoidosis-associated pulmonary hypertension (SAPH) was simply considered to be secondary to lung disease [<xref rid="B2-diagnostics-13-03132" ref-type="bibr">2</xref>], but later observations showed that 30&#8211;40% of SAPH patients do not have lung fibrosis, and even 9&#8211;12% do not exhibit any lung parenchyma involvement [<xref rid="B3-diagnostics-13-03132" ref-type="bibr">3</xref>,<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B5-diagnostics-13-03132" ref-type="bibr">5</xref>,<xref rid="B6-diagnostics-13-03132" ref-type="bibr">6</xref>,<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B9-diagnostics-13-03132" ref-type="bibr">9</xref>]. Currently, it is acknowledged that sarcoidosis may lead to PH via multiple mechanisms, resulting in various forms of PH [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. In PH clinical classification, SAPH belongs to WHO group 5, i.e., PH with unclear and/or multifactorial mechanisms [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>]. The heterogeneity and complexity of SAPH are due to the heterogeneity of sarcoidosis itself. This systemic inflammatory disease of unknown cause may affect any organ, giving various clinical manifestations and consequences. Beginning with inflammation in the form of noncaseating granulomas, sarcoidosis may lead to fibrosis and/or failure of affected structures [<xref rid="B11-diagnostics-13-03132" ref-type="bibr">11</xref>,<xref rid="B12-diagnostics-13-03132" ref-type="bibr">12</xref>]. Both inflammation and fibrosis play a role in SPAH development. SAPH may result from parenchymal lung disease, the extrinsic compression of pulmonary vessels, pulmonary vasculopathy, LV dysfunction, or portal hypertension [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. Sarcoidosis increases the risk of PH development by 3.2 times [<xref rid="B13-diagnostics-13-03132" ref-type="bibr">13</xref>]. Additionally, sarcoidosis is associated with a three-fold increased risk of thromboembolic disease, which may implicate a higher risk for chronic thromboembolic pulmonary hypertension [<xref rid="B14-diagnostics-13-03132" ref-type="bibr">14</xref>,<xref rid="B15-diagnostics-13-03132" ref-type="bibr">15</xref>]. Also, the prevalence of obstructive sleep apnoea in sarcoidosis has been reported to be as high as 88% [<xref rid="B16-diagnostics-13-03132" ref-type="bibr">16</xref>], and this could be another possible mechanism inducing SAPH. However, the impact of these comorbidities has not been studied enough.</p><p>Sarcoidosis is a rare disease, and its incidence and prevalence vary broadly depending on geographic region, race, age, and sex. The highest rates are reported in Northern Europe and in African American individuals, and the lowest in Asia. The estimated incidence in Europe ranges between 1 and 19 cases per 100,000 persons/year [<xref rid="B12-diagnostics-13-03132" ref-type="bibr">12</xref>,<xref rid="B17-diagnostics-13-03132" ref-type="bibr">17</xref>]. Resting SAPH prevalence, according to the previous PH definition, was estimated to be 6.4% in the general sarcoidosis population and 62.3% in the population with advanced pulmonary disease [<xref rid="B18-diagnostics-13-03132" ref-type="bibr">18</xref>]. Pre-capillary PH dominated in SAPH [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B18-diagnostics-13-03132" ref-type="bibr">18</xref>,<xref rid="B19-diagnostics-13-03132" ref-type="bibr">19</xref>], and 46% of pre-capillary SAPH was moderate to severe as defined using an mPAP &gt; 35 mmHg [<xref rid="B5-diagnostics-13-03132" ref-type="bibr">5</xref>]. An increase in the resting SAPH prevalence by around 60% may be anticipated following the new PH definition [<xref rid="B20-diagnostics-13-03132" ref-type="bibr">20</xref>], and a proportion of sarcoidosis patients with exercise PH is yet to be determined [<xref rid="B21-diagnostics-13-03132" ref-type="bibr">21</xref>].</p><p>It remains unknown why some patients develop PH and some do not, despite the same demographic and sarcoidosis-related characteristics [<xref rid="B5-diagnostics-13-03132" ref-type="bibr">5</xref>]. The role of genetic susceptibility is still under research [<xref rid="B22-diagnostics-13-03132" ref-type="bibr">22</xref>].</p><p>SAPH is an independent risk factor for mortality in sarcoidosis and carries up to a 10-fold increase in the risk of death [<xref rid="B13-diagnostics-13-03132" ref-type="bibr">13</xref>,<xref rid="B23-diagnostics-13-03132" ref-type="bibr">23</xref>,<xref rid="B24-diagnostics-13-03132" ref-type="bibr">24</xref>,<xref rid="B25-diagnostics-13-03132" ref-type="bibr">25</xref>,<xref rid="B26-diagnostics-13-03132" ref-type="bibr">26</xref>,<xref rid="B27-diagnostics-13-03132" ref-type="bibr">27</xref>,<xref rid="B28-diagnostics-13-03132" ref-type="bibr">28</xref>]. An estimated 5-year transplant-free survival in SAPH is 40&#8211;62% [<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B19-diagnostics-13-03132" ref-type="bibr">19</xref>,<xref rid="B29-diagnostics-13-03132" ref-type="bibr">29</xref>,<xref rid="B30-diagnostics-13-03132" ref-type="bibr">30</xref>]. The predictors of adverse outcomes in SAPH are WHO-functional class 4, right ventricular dysfunction, moderate or severe lung fibrosis, 6 min walking distance (6MWD) &lt; 300 m, total lung diffusion capacity for carbon monoxide (TLco) &lt; 35%pred, and a persistent high level of N-terminal brain natriuretic pro-peptide (NT-proBNP) level after 3&#8211;9 months of treatment with vasodilators [<xref rid="B6-diagnostics-13-03132" ref-type="bibr">6</xref>,<xref rid="B19-diagnostics-13-03132" ref-type="bibr">19</xref>,<xref rid="B30-diagnostics-13-03132" ref-type="bibr">30</xref>].</p><p>There are no strong recommendations for SAPH treatment, as evidence from randomised clinical trials (RCT) is limited [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. Given the diversity of mechanisms leading to SAPH, the most current guidelines advocate phenotyping, i.e., searching for the predominant mechanisms of SAPH in each patient and then applying the most appropriate treatment directed to the underlying condition [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. Lung transplantation (LTx) should be considered if all other available modalities of treatment fail [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>].</p><p>Unfortunately, SAPH phenotyping is not a straightforward process. It requires sophisticated diagnostic modalities, and the assessment of some elements, such as vascular remodelling, pulmonary angiitis, or microangiopathy, remains beyond the capability of non-invasive tools. Mathijssen et al. have shared the outcome of their attempt to assess the prevalence of different SAPH phenotypes in a single-centre cohort of 40 patients [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>].</p></sec><sec id="sec2-diagnostics-13-03132"><title>2. SAPH According to the Predominant Pathophysiological Mechanism</title><sec id="sec2dot1-diagnostics-13-03132"><title>2.1. Parenchymal Lung Disease</title><p>Sarcoidosis affects the lungs and thoracic lymph nodes in more than 90% of patients [<xref rid="B31-diagnostics-13-03132" ref-type="bibr">31</xref>]. In the majority of affected people, acute granulomatous inflammation is self-limiting and resolves spontaneously with time. In about one-third of the cases, the inflammation becomes chronic. Subsequently, about 20% of patients with persistent inflammation develop lung fibrosis [<xref rid="B32-diagnostics-13-03132" ref-type="bibr">32</xref>]. Based on chest X-ray appearance, five stages of intrathoracic sarcoidosis are distinguished, as presented in <xref rid="diagnostics-13-03132-t002" ref-type="table">Table 2</xref> [<xref rid="B33-diagnostics-13-03132" ref-type="bibr">33</xref>].</p><p>Pulmonary involvement increases the risk of PH almost five times compared to non-pulmonary sarcoidosis. In the population from the Nationwide Inpatient Sample 2016&#8211;2018, the prevalence of PH was 19% in cases with pulmonary sarcoidosis and 3.5% with non-pulmonary sarcoidosis; however, there was no information on pulmonary sarcoidosis staging [<xref rid="B34-diagnostics-13-03132" ref-type="bibr">34</xref>]. In published research, 65&#8211;80% of sarcoidosis patients with pre-capillary PH confirmed by RHC had stage 4 disease, as assessed using either chest X-ray or HRCT [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B5-diagnostics-13-03132" ref-type="bibr">5</xref>,<xref rid="B6-diagnostics-13-03132" ref-type="bibr">6</xref>,<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>]. In about half of these patients, PH was mild, i.e., mPAP &#8804; 35 mmHg [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B5-diagnostics-13-03132" ref-type="bibr">5</xref>]. Surprisingly, no correlation could be found between mPAP or pulmonary vascular resistance (PVR) and spirometric or plethysmographic parameters, and patients with similar radiologic and pulmonary function characteristics behaved differently in terms of PH development [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B5-diagnostics-13-03132" ref-type="bibr">5</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B24-diagnostics-13-03132" ref-type="bibr">24</xref>,<xref rid="B35-diagnostics-13-03132" ref-type="bibr">35</xref>].</p><p>The ablation, compression, and distortion of pulmonary vessels, together with hypoxic pulmonary vasoconstriction (HPV), are believed to be the first elements of the pre-capillary PH development pathway in the parenchymal phenotype of SAPH by analogy to other chronic lung diseases [<xref rid="B36-diagnostics-13-03132" ref-type="bibr">36</xref>,<xref rid="B37-diagnostics-13-03132" ref-type="bibr">37</xref>]. HPV is a compensatory mechanism to maintain ventilation/perfusion homeostasis by diverting blood flow from more seriously to less seriously affected lung segments. Depending on the magnitude of the pulmonary vascular bed loss and the magnitude of HPV, pulmonary artery pressure may increase, albeit usually mildly. In some yet not identified circumstances, the increased shear stress from high blood flow induces a response from pulmonary vessels that leads to their remodelling and irreversible structural changes, resulting in significant elevations of PVR and PAP. This interaction between increasing shear stress and pulmonary vasculature remodelling may continue in a vicious cycle [<xref rid="B38-diagnostics-13-03132" ref-type="bibr">38</xref>,<xref rid="B39-diagnostics-13-03132" ref-type="bibr">39</xref>,<xref rid="B40-diagnostics-13-03132" ref-type="bibr">40</xref>,<xref rid="B41-diagnostics-13-03132" ref-type="bibr">41</xref>,<xref rid="B42-diagnostics-13-03132" ref-type="bibr">42</xref>]. Remodelling involves all levels of the pulmonary vasculature and all layers of the vessel walls [<xref rid="B40-diagnostics-13-03132" ref-type="bibr">40</xref>,<xref rid="B43-diagnostics-13-03132" ref-type="bibr">43</xref>,<xref rid="B44-diagnostics-13-03132" ref-type="bibr">44</xref>,<xref rid="B45-diagnostics-13-03132" ref-type="bibr">45</xref>]. <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) uptake was found on positron emission tomography (PET) in the pulmonary artery wall in 19% of 175 sarcoidosis patients, and these patients had higher PAP and PVR compared to patients without the uptake [<xref rid="B46-diagnostics-13-03132" ref-type="bibr">46</xref>]. The meaning of this phenomenon is not clear, but one of the theories is that it reflects the inflammation caused by the shear stress and could be helpful in the early detection of developing PH [<xref rid="B47-diagnostics-13-03132" ref-type="bibr">47</xref>].</p><p>The distinctive features of sarcoid inflammation and fibrosis, including a specific lymphangitic fashion of distribution, can be responsible for differences observed between SAPH and PH due to other interstitial lung diseases (ILDs). For example, the same degree of fibrosis is associated with higher PAP in sarcoidosis than in idiopathic pulmonary fibrosis (IPF) and other ILDs [<xref rid="B48-diagnostics-13-03132" ref-type="bibr">48</xref>,<xref rid="B49-diagnostics-13-03132" ref-type="bibr">49</xref>]. The predilection to bronchovascular bundles, septa, and subpleural regions may be associated with a larger direct impact on nearby pulmonary vessels [<xref rid="B50-diagnostics-13-03132" ref-type="bibr">50</xref>].</p><p>A clear definition of a parenchymal SAPH phenotype is lacking. Mathijssen et al. adopted the recommendations regarding PH associated with chronic lung diseases from the latest World Symposium on PH to define the criteria of a parenchymal SAPH. These criteria include pre-capillary PH and moderate to severe pulmonary parenchymal disease; the latter was defined as stage 3 or 4 pulmonary sarcoidosis or severe obstructive (forced expiratory volume in 1 s (FEV<sub>1</sub>) &#8804; 60%pred) or restrictive disease (forced vital capacity (FVC) &#8804; 70%pred). They found the parenchymal phenotype in 73% of the patients from their SAPH cohort. Interestingly, not all stage 4 patients with pre-capillary PH were classified as the parenchymal phenotype despite the used definition; 17% of them were assigned to a compression phenotype, and one was diagnosed with chronic thromboembolic PH. Patients with stage 2 pulmonary sarcoidosis also fulfilled the criteria of the parenchymal phenotype. Additionally, one patient with stage 2 disease was categorised as having a parenchymal phenotype despite not fulfilling the criteria, but it was decided that this category was the best fit [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>].</p><p>There are no evidence-based recommendations for the treatment of SAPH with predominant parenchymal causes. As for now, the treatment of underlying diseases and the symptomatic treatment of respiratory and/or heart failure, if needed, is a standard of care [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. If SAPH is accompanied by active parenchymal inflammation, treatment with glucocorticoids and/or other anti-inflammatory medications is warranted. However, there is no solid proof of their effectiveness [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>,<xref rid="B31-diagnostics-13-03132" ref-type="bibr">31</xref>,<xref rid="B51-diagnostics-13-03132" ref-type="bibr">51</xref>,<xref rid="B52-diagnostics-13-03132" ref-type="bibr">52</xref>]. The use of immunosuppressive therapy in a SAPH setting is very common, it was applied in 26%-77% of SAPH patients from registries [<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B19-diagnostics-13-03132" ref-type="bibr">19</xref>] and in up to 80% of retrospectively analysed cohorts [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>], including SAPH with fibrotic pulmonary disease [<xref rid="B53-diagnostics-13-03132" ref-type="bibr">53</xref>]. Reports on treatment outcomes are very limited and divergent [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>]. Of note, haemodynamic improvement has been observed in some SAPH patients with stage 4 pulmonary disease, and reporting authors speculated the effect depended on a component of active inflammation [<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>]. There is clinical, histopathological, and metabolic evidence that the majority of patients with fibrotic pulmonary sarcoidosis have concomitant active granulomatous inflammation [<xref rid="B54-diagnostics-13-03132" ref-type="bibr">54</xref>,<xref rid="B55-diagnostics-13-03132" ref-type="bibr">55</xref>,<xref rid="B56-diagnostics-13-03132" ref-type="bibr">56</xref>,<xref rid="B57-diagnostics-13-03132" ref-type="bibr">57</xref>,<xref rid="B58-diagnostics-13-03132" ref-type="bibr">58</xref>,<xref rid="B59-diagnostics-13-03132" ref-type="bibr">59</xref>]. Up to 85% of patients with stage 4 pulmonary sarcoidosis showed active inflammation in lung parenchyma on <sup>18</sup>F-FDG-PET [<xref rid="B57-diagnostics-13-03132" ref-type="bibr">57</xref>,<xref rid="B58-diagnostics-13-03132" ref-type="bibr">58</xref>,<xref rid="B59-diagnostics-13-03132" ref-type="bibr">59</xref>]. Volumetric quantitative <sup>18</sup>F-FDG-PET measurements showed a similar burden of active pulmonary inflammation in stage 4 as in stages 2&#8211;3, with the extent of the inflammation area corresponding to about 45% of lung volume [<xref rid="B57-diagnostics-13-03132" ref-type="bibr">57</xref>]. Distinguishing the burnt-out disease from fibrotic pulmonary sarcoidosis with smouldering inflammation can be challenging when based only on conventional radiologic studies [<xref rid="B60-diagnostics-13-03132" ref-type="bibr">60</xref>,<xref rid="B61-diagnostics-13-03132" ref-type="bibr">61</xref>]. The usefulness of serum biomarkers in predicting the activity of sarcoidosis has been researched, but none appeared to be accurate enough [<xref rid="B57-diagnostics-13-03132" ref-type="bibr">57</xref>,<xref rid="B58-diagnostics-13-03132" ref-type="bibr">58</xref>,<xref rid="B59-diagnostics-13-03132" ref-type="bibr">59</xref>,<xref rid="B62-diagnostics-13-03132" ref-type="bibr">62</xref>,<xref rid="B63-diagnostics-13-03132" ref-type="bibr">63</xref>,<xref rid="B64-diagnostics-13-03132" ref-type="bibr">64</xref>,<xref rid="B65-diagnostics-13-03132" ref-type="bibr">65</xref>].</p><p>Antifibrotic agents could potentially play a role in the treatment of SAPH due to lung fibrosis [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>], but this has not been properly addressed yet. Only 12 patients with fibrotic pulmonary sarcoidosis, less than 2% of the studied population, were enrolled into the INBUILD study, RCT that investigated the efficacy of nintedanib in progressive fibrotic ILDs. Four were in the active treatment arm, and eight in the placebo arm. That did not allow for significant conclusions on the therapeutic effect of nintedanib in sarcoidosis [<xref rid="B66-diagnostics-13-03132" ref-type="bibr">66</xref>,<xref rid="B67-diagnostics-13-03132" ref-type="bibr">67</xref>,<xref rid="B68-diagnostics-13-03132" ref-type="bibr">68</xref>]. No further patients with progressive fibrotic pulmonary sarcoidosis treated with nintedanib were identified in the systematic search through the literature until Dec 2020 [<xref rid="B68-diagnostics-13-03132" ref-type="bibr">68</xref>]. Patients with sarcoidosis were not included in the RELIF study, which investigated pirfenidone in fibrotic ILDs [<xref rid="B69-diagnostics-13-03132" ref-type="bibr">69</xref>]. The only RCT on pirfenidone in progressive fibrotic pulmonary sarcoidosis had to be stopped due to the COVID-19 pandemic after only 16 patients were enrolled. Fourteen patients, ten receiving pirfenidone and four receiving placebo, completed 18 months of the trial [<xref rid="B70-diagnostics-13-03132" ref-type="bibr">70</xref>]. The rationale for the common use of anti-fibrotic drugs in pulmonary sarcoidosis is not strong. The progressive phenotype of fibrosis in sarcoidosis is not frequent compared to other fibrosing ILDs, it has been seen in about 15&#8211;50% of patients with fibrotic pulmonary sarcoidosis [<xref rid="B28-diagnostics-13-03132" ref-type="bibr">28</xref>,<xref rid="B71-diagnostics-13-03132" ref-type="bibr">71</xref>,<xref rid="B72-diagnostics-13-03132" ref-type="bibr">72</xref>]. Only one patient fulfilling the criteria of progressing fibrotic pulmonary sarcoidosis was found among 167 patients with progressive fibrosing ILDs hospitalised in the years 2012 and 2021 in two hospitals in Osaka, Japan [<xref rid="B73-diagnostics-13-03132" ref-type="bibr">73</xref>]. The usual interstitial pneumonia (UIP) pattern is very rare in fibrotic pulmonary sarcoidosis [<xref rid="B28-diagnostics-13-03132" ref-type="bibr">28</xref>,<xref rid="B55-diagnostics-13-03132" ref-type="bibr">55</xref>,<xref rid="B68-diagnostics-13-03132" ref-type="bibr">68</xref>,<xref rid="B74-diagnostics-13-03132" ref-type="bibr">74</xref>]. It is still unknown whether these rare cases of UIP pattern in sarcoidosis are a form of fibrotic sarcoidosis, constitute a separate condition called combined sarcoidosis and IPF (CSIPF), or are only a fortuitous overlap [<xref rid="B74-diagnostics-13-03132" ref-type="bibr">74</xref>]. If fibroblastic foci and honeycombing are present in pulmonary sarcoidosis, they are less numerous [<xref rid="B55-diagnostics-13-03132" ref-type="bibr">55</xref>,<xref rid="B56-diagnostics-13-03132" ref-type="bibr">56</xref>]. Fibroblastic foci from lungs with end-stage sarcoidosis and lungs with IPF differ to some extent in gene and protein expression [<xref rid="B75-diagnostics-13-03132" ref-type="bibr">75</xref>]. Reports on the relationship of the UIP pattern with progressive fibrotic pulmonary sarcoidosis are inconsistent, although the UIP pattern is associated with a worse prognosis [<xref rid="B28-diagnostics-13-03132" ref-type="bibr">28</xref>,<xref rid="B74-diagnostics-13-03132" ref-type="bibr">74</xref>]. Also, not much is known about the impact of progressive fibrotic pulmonary sarcoidosis on PH. In one report, PH was more prevalent in progressive (24%) compared to non-progressive (10%) fibrotic pulmonary sarcoidosis, but that difference was not statistically significant [<xref rid="B28-diagnostics-13-03132" ref-type="bibr">28</xref>].</p><p>The use of pulmonary vasodilators in SAPH is still an open and controversial topic. Given the vascular remodelling processes appearing in SAPH on one hand, and the beneficial outcome from treatment with inhaled NO, inhaled treprostinil, and sildenafil shown in group 3 PH [<xref rid="B76-diagnostics-13-03132" ref-type="bibr">76</xref>,<xref rid="B77-diagnostics-13-03132" ref-type="bibr">77</xref>,<xref rid="B78-diagnostics-13-03132" ref-type="bibr">78</xref>] on the other hand, some advantages from pulmonary vasodilator could be expected in the parenchymal phenotype of SAPH. The majority of reports on vasodilators in SAPH are retrospective case reports with inconsistent observations regarding the efficacy of the treatment [<xref rid="B6-diagnostics-13-03132" ref-type="bibr">6</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B29-diagnostics-13-03132" ref-type="bibr">29</xref>,<xref rid="B30-diagnostics-13-03132" ref-type="bibr">30</xref>,<xref rid="B79-diagnostics-13-03132" ref-type="bibr">79</xref>,<xref rid="B80-diagnostics-13-03132" ref-type="bibr">80</xref>,<xref rid="B81-diagnostics-13-03132" ref-type="bibr">81</xref>,<xref rid="B82-diagnostics-13-03132" ref-type="bibr">82</xref>,<xref rid="B83-diagnostics-13-03132" ref-type="bibr">83</xref>,<xref rid="B84-diagnostics-13-03132" ref-type="bibr">84</xref>,<xref rid="B85-diagnostics-13-03132" ref-type="bibr">85</xref>,<xref rid="B86-diagnostics-13-03132" ref-type="bibr">86</xref>]. Few prospective open-label studies were not conclusive either [<xref rid="B87-diagnostics-13-03132" ref-type="bibr">87</xref>,<xref rid="B88-diagnostics-13-03132" ref-type="bibr">88</xref>,<xref rid="B89-diagnostics-13-03132" ref-type="bibr">89</xref>]. First, inhaled iloprost was assessed in the trial that enrolled 22 patients, but only 15 completed the 16-week therapy. Six patients showed haemodynamic improvement expressed as a decrease in PVR of &#8805;20%, and five also had a reduction in mPAP of &#8805;5 mmHg. Only three patients improved 6MWD by &#8805;30 m. A significant improvement in quality of life (QoL) was noted in some patients [<xref rid="B87-diagnostics-13-03132" ref-type="bibr">87</xref>]. Next, ambrisentan was studied in a cohort of 21 patients, of which only 48% completed the 24-week therapy. No significant improvement was achieved in 6MWD, NT-proBNP, TLco, or QoL [<xref rid="B88-diagnostics-13-03132" ref-type="bibr">88</xref>]. The last open-label trial was designed to study the efficacy of tadalafil, and 12 patients were enrolled, but only a small portion completed the 24-week period of therapy. No benefit was shown [<xref rid="B89-diagnostics-13-03132" ref-type="bibr">89</xref>]. Only two RCTs dedicated to pulmonary vasodilators use in SAPH have been conducted so far, one with bosentan and the other with riociguat [<xref rid="B53-diagnostics-13-03132" ref-type="bibr">53</xref>,<xref rid="B90-diagnostics-13-03132" ref-type="bibr">90</xref>]. The trial with bosentan involved 35 patients, 23 assigned to the active treatment arm and 12 to the placebo arm, 50% with fibrotic lung disease, and lasted for 16 weeks. Bosentan improved haemodynamic parameters but had no effect on 6MWD [<xref rid="B90-diagnostics-13-03132" ref-type="bibr">90</xref>]. The trial with riociguat enrolled 16 SAPH patients, randomised 1:1 to active treatment or placebo, 75% with lung fibrosis, and lasted 1 year. Riociguat improved 6MWD and was effective in preventing clinical worsening. Changes in pulmonary haemodynamics were not assessed [<xref rid="B53-diagnostics-13-03132" ref-type="bibr">53</xref>]. Overall, published reports indicate that the use of pulmonary vasodilators in SAPH is safe and well tolerated [<xref rid="B6-diagnostics-13-03132" ref-type="bibr">6</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B30-diagnostics-13-03132" ref-type="bibr">30</xref>,<xref rid="B53-diagnostics-13-03132" ref-type="bibr">53</xref>,<xref rid="B79-diagnostics-13-03132" ref-type="bibr">79</xref>,<xref rid="B80-diagnostics-13-03132" ref-type="bibr">80</xref>,<xref rid="B81-diagnostics-13-03132" ref-type="bibr">81</xref>,<xref rid="B82-diagnostics-13-03132" ref-type="bibr">82</xref>,<xref rid="B83-diagnostics-13-03132" ref-type="bibr">83</xref>,<xref rid="B84-diagnostics-13-03132" ref-type="bibr">84</xref>,<xref rid="B85-diagnostics-13-03132" ref-type="bibr">85</xref>,<xref rid="B86-diagnostics-13-03132" ref-type="bibr">86</xref>,<xref rid="B87-diagnostics-13-03132" ref-type="bibr">87</xref>,<xref rid="B88-diagnostics-13-03132" ref-type="bibr">88</xref>,<xref rid="B89-diagnostics-13-03132" ref-type="bibr">89</xref>,<xref rid="B90-diagnostics-13-03132" ref-type="bibr">90</xref>]. The risk of blood oxygen saturation worsening is minimal, practically limited to the use of prostacyclin analogues administered either intravenously or subcutaneously, and even in those cases, it was only transient, resolving within 3&#8211;4 weeks [<xref rid="B53-diagnostics-13-03132" ref-type="bibr">53</xref>,<xref rid="B84-diagnostics-13-03132" ref-type="bibr">84</xref>,<xref rid="B89-diagnostics-13-03132" ref-type="bibr">89</xref>,<xref rid="B90-diagnostics-13-03132" ref-type="bibr">90</xref>]. The limitations of available retrospective and prospective studies include not only small samples and diversity of analysed end-points but also heterogeneity with respect to pulmonary sarcoidosis stages and the concomitant use of immunosuppressive medications, which could have had a significant impact on the findings. The results of three phase 2 studies are awaited: (i) SPHINX trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03942211">NCT03942211</ext-link>), an RCT to assess efficacy and safety of oral selexipag in SAPH, (ii) SAPPHIRE trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03814317">NCT03814317</ext-link>), an open-label study with inhaled treprostinil for stage 4 pulmonary sarcoidosis with pulmonary hypertension, and (iii) an open-label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (NO) in subjects with PH associated with pulmonary fibrosis or sarcoidosis on long term oxygen therapy followed by long term extension study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03727451">NCT03727451</ext-link>). It is also noteworthy that attention has been paid to the potential anti-inflammatory and anti-fibrotic effects of vasodilators [<xref rid="B91-diagnostics-13-03132" ref-type="bibr">91</xref>,<xref rid="B92-diagnostics-13-03132" ref-type="bibr">92</xref>,<xref rid="B93-diagnostics-13-03132" ref-type="bibr">93</xref>,<xref rid="B94-diagnostics-13-03132" ref-type="bibr">94</xref>]. Inhaled treprostinil improved FVC %pred and lowered the risk of clinical worsening and exacerbation of ILDs underlying PH in the INCREASE study [<xref rid="B92-diagnostics-13-03132" ref-type="bibr">92</xref>]. Treatment with PH-targeted medications prevented FVC decline in patients with SAPH evaluated for LTx [<xref rid="B93-diagnostics-13-03132" ref-type="bibr">93</xref>]. On the other hand, a prospective 12-month phase 2 RCT found no evidence for the efficacy of bosentan as an anti-fibrotic treatment for steroid-resistant pulmonary sarcoidosis [<xref rid="B94-diagnostics-13-03132" ref-type="bibr">94</xref>]. Change in FEV<sub>1</sub> and FVC has been planned as a secondary end-point in the above-mentioned ongoing SAPPIRE trial with inhaled treprostinil for SAPH. Currently, there are no approved PH-targeted therapies for SAPH. Off-label uses of pulmonary vasodilators may be considered for symptomatic patients on a case-by-case basis [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. They may be also useful in patients referred for LTx, potentially decreasing mortality while waiting on the list [<xref rid="B93-diagnostics-13-03132" ref-type="bibr">93</xref>].</p></sec><sec id="sec2dot2-diagnostics-13-03132"><title>2.2. Extrinsic Compression of Pulmonary Vessels</title><p>The patency of pulmonary vessels, both arteries and veins, may be compromised by extrinsic compression caused by active sarcoidosis-based inflammation, fibrous lung parenchyma, lymph nodes, or fibrosing mediastinitis. The prevalence of mediastinal lymphadenopathy in sarcoidosis exceeds 90% [<xref rid="B33-diagnostics-13-03132" ref-type="bibr">33</xref>]. The prevalence of fibrosing mediastinitis is unknown, but sarcoidosis may account for about 11% of fibrosing mediastinitis [<xref rid="B95-diagnostics-13-03132" ref-type="bibr">95</xref>] and 42% of fibrosing mediastinitis causing PH [<xref rid="B96-diagnostics-13-03132" ref-type="bibr">96</xref>]. The phenomenon of extrinsic vessel compression and its significance in SAPH development is poorly explored and understood [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>,<xref rid="B97-diagnostics-13-03132" ref-type="bibr">97</xref>,<xref rid="B98-diagnostics-13-03132" ref-type="bibr">98</xref>,<xref rid="B99-diagnostics-13-03132" ref-type="bibr">99</xref>]. The frequent compression of proximal pulmonary arteries, occasionally with luminal obliteration, has been revealed in the postmortem examination of the lungs of sarcoidosis patients [<xref rid="B100-diagnostics-13-03132" ref-type="bibr">100</xref>]. Mathijseen et al. defined compression phenotype as a precapillary PH with the compression of central or segmental pulmonary arteries in imaging studies. They found this phenotype in 15% of their patients, with compression caused by either lung fibrosis, fibrosing mediastinitis, calcified lymph nodes, or active inflammatory masses. Among these six patients, five had stage 4 pulmonary sarcoidosis, and one had stage 1 disease. In two patients, including one with stage 1 pulmonary sarcoidosis, compressing structures were metabolically active on <sup>18</sup>F-FDG-PET [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>]. In a French cohort of 126 patients with severe pre-capillary SAPH, 4% had extrinsic compression of pulmonary arteries due to lymphadenopathy (two cases) or fibrosing mediastinitis (three cases). An increased uptake of <sup>18</sup>F-FDG on PET was present in three patients: two with compressive lymph nodes and one with fibrosing mediastinitis [<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>]. In another cohort of 22 pre-capillary SAPH patients, the extrinsic compression of large pulmonary arteries by lymph nodes was recognised in 14% of the patients, all stage 4 disease [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>]. In a meta-analysis performed on 17 SAPH patients who underwent pulmonary angioplasty for focal stenosis or external compression of the pulmonary vessels, the most frequently affected were the right pulmonary artery and its branches, and the least frequently affected were the pulmonary veins. Usually, multiple bilateral stenosis was present [<xref rid="B97-diagnostics-13-03132" ref-type="bibr">97</xref>]. Extrinsic pulmonary vessel compression may appear in any stage of pulmonary sarcoidosis [<xref rid="B98-diagnostics-13-03132" ref-type="bibr">98</xref>] and may be detected on contrast-enhanced CT, HRCT, or pulmonary angiography [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B97-diagnostics-13-03132" ref-type="bibr">97</xref>,<xref rid="B98-diagnostics-13-03132" ref-type="bibr">98</xref>].</p><p>The assumption that the compressive phenotype of SAPH is confined to pre-capillary PH seems controversial and may be responsible for the underestimation of the prevalence of this phenotype. In a cohort of 27 patients with fibrosing mediastinitis and PH, 18% had post-capillary PH without concomitant cardiac disease. Sarcoidosis patients accounted for 48% of the whole group. In 52% of the patients, severe compression of pulmonary veins was present, the most probable cause of elevated pulmonary arterial wedge pressure (PAWP) [<xref rid="B96-diagnostics-13-03132" ref-type="bibr">96</xref>].</p><p>Immunosuppressive treatment was reported to be beneficial in some patients with extrinsic pulmonary vessel compression but ineffective in others [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B96-diagnostics-13-03132" ref-type="bibr">96</xref>,<xref rid="B98-diagnostics-13-03132" ref-type="bibr">98</xref>,<xref rid="B99-diagnostics-13-03132" ref-type="bibr">99</xref>]. Such treatment may be effective in acute granulomatous inflammation but has no effect when fibrosis develops [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B96-diagnostics-13-03132" ref-type="bibr">96</xref>,<xref rid="B98-diagnostics-13-03132" ref-type="bibr">98</xref>,<xref rid="B99-diagnostics-13-03132" ref-type="bibr">99</xref>]. The experience with <sup>18</sup>F-FDG-PET as a tool predicting response to the treatment is limited and shows not satisfying accuracy [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>,<xref rid="B96-diagnostics-13-03132" ref-type="bibr">96</xref>]. Pulmonary vasodilators have been tried in a few cases, but the small sample did not allow for any conclusions [<xref rid="B96-diagnostics-13-03132" ref-type="bibr">96</xref>]. Balloon angioplasty with or without stenting seems to give significant haemodynamic and functional improvement [<xref rid="B97-diagnostics-13-03132" ref-type="bibr">97</xref>,<xref rid="B98-diagnostics-13-03132" ref-type="bibr">98</xref>]; however, currently, it is an off-label treatment option to be considered only in carefully selected patients with focal and critical vessel stenosis [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>,<xref rid="B97-diagnostics-13-03132" ref-type="bibr">97</xref>]. It is recommended to evaluate for pulmonary artery stenosis or mediastinal compression on chest imaging in all SAPH patients [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>].</p></sec><sec id="sec2dot3-diagnostics-13-03132"><title>2.3. Pulmonary Angiitis and Microangiopathy</title><p>Mathijssen et al. defined a vasculopathy phenotype as a pre-capillary PH with PVR &gt; 3 Wu, no or mild pulmonary disease, and excluded other causes of PH. Based on that, they classified only 1 patient of the group of 40 as a suspected vasculopathy phenotype [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>]. Yet, the lung pathological evaluation proves that intrinsic vascular involvement at all levels of pulmonary vasculature is very common in sarcoidosis. It appears in two forms: sarcoidosis-specific granulomatous angiitis and non-specific microangiopathy [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B100-diagnostics-13-03132" ref-type="bibr">100</xref>,<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>,<xref rid="B102-diagnostics-13-03132" ref-type="bibr">102</xref>]. Granulomatous pulmonary angiitis means the presence of granulomas within walls of blood vessels with the destruction of lamina elastica and was found in 100% of sarcoidosis cases in specimens from autopsy series [<xref rid="B100-diagnostics-13-03132" ref-type="bibr">100</xref>], in 69% of specimens from open lung biopsies [<xref rid="B102-diagnostics-13-03132" ref-type="bibr">102</xref>], and in 41% of transbronchial biopsies [<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>]. It was also found in 80% of explanted SAPH lungs [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>]. Both granulomas and healed lesions of various stages were observed, often coexisting. Granulomatous vascular involvement correlated positively with the extent of granulomas in lung parenchyma, but there was no correlation between the occurrence of granulomatous angiitis and radiographic pulmonary sarcoidosis stages [<xref rid="B100-diagnostics-13-03132" ref-type="bibr">100</xref>,<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>]. Interestingly, venous involvement predominated and accounted for up to 90% of cases [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B100-diagnostics-13-03132" ref-type="bibr">100</xref>,<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>,<xref rid="B102-diagnostics-13-03132" ref-type="bibr">102</xref>]. Granulomas were found in vessels of all calibres, but 75% of the involved veins and 54% of arteries were less than 100 &#181;m in diameter [<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>]. Microangiopathy refers to the alterations of endothelial and basement membrane of precapillary, capillary, and postcapillary pulmonary vessels and was found in 35% of transbronchial biopsy specimens from patients with sarcoidosis [<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>] and 100% of explanted lungs of five patients with SAPH [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>]. Both angiitis and microangiopathy caused vessel occlusion and destruction [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B45-diagnostics-13-03132" ref-type="bibr">45</xref>,<xref rid="B50-diagnostics-13-03132" ref-type="bibr">50</xref>,<xref rid="B100-diagnostics-13-03132" ref-type="bibr">100</xref>,<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>,<xref rid="B102-diagnostics-13-03132" ref-type="bibr">102</xref>,<xref rid="B103-diagnostics-13-03132" ref-type="bibr">103</xref>,<xref rid="B104-diagnostics-13-03132" ref-type="bibr">104</xref>]. Plexiform lesions were not typically seen in sarcoidosis-associated vasculopathy [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B100-diagnostics-13-03132" ref-type="bibr">100</xref>,<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>]; however, venous involvement with vessel obliteration and subsequent capillary congestion may resemble pulmonary veno-occlusive disease (PVOD) [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B105-diagnostics-13-03132" ref-type="bibr">105</xref>,<xref rid="B106-diagnostics-13-03132" ref-type="bibr">106</xref>]. The assumption that pulmonary vasculopathy is to be expected only in cases with mild pulmonary disease and severe PH, in the absence of other possible causes, is debatable in light of the facts presented above. Most probably, it contributes significantly to the development of SAPH believed to be of predominantly different phenotypes, and it may be responsible for severe or out of proportion to perceptible factors PH. Also, given the vast venous involvement, a post-capillary PH could be expected. A negative correlation between mPAP or PVR and TLco was found in SAPH, and septal lines and ground glass opacifications appeared more often on the lung HRCT of SAPH patients compared to sarcoidosis patients without PH [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>]. These clinical and radiologic features are known to occur commonly in PH with overt involvement of pulmonary veins [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>]. Pulmonary vasculopathy is potentially the most underappreciated mechanism of SAPH, as it is difficult to establish the diagnosis and to assess the extent of vascular involvement antemortem.</p><p>Immunosuppressive agents are suggested as the first-line treatment when sarcoidosis vasculopathy is suspected, with the option of the pulmonary vasodilators used in some patients [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. In patients with venous involvement resembling PVOD, pulmonary vasodilators should be used carefully in order to avoid worsening pulmonary congestion [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>].</p></sec><sec id="sec2dot4-diagnostics-13-03132"><title>2.4. LV Dysfunction</title><p>It is believed that post-capillary SAPH results from cardiac involvement in the course of sarcoidosis that causes LV function impairment. This hypothetical cause-and-effect relationship has not been validated practically, though no studies addressing this topic can be found. Cardiac involvement has been observed in up to 27% of Caucasian and African American sarcoidosis patients and even up to 80% of Japanese patients; in the majority of them, it was clinically silent [<xref rid="B107-diagnostics-13-03132" ref-type="bibr">107</xref>,<xref rid="B108-diagnostics-13-03132" ref-type="bibr">108</xref>,<xref rid="B109-diagnostics-13-03132" ref-type="bibr">109</xref>]. Post-capillary PH accounted for 7&#8211;28% of SAPH cases in reported groups [<xref rid="B5-diagnostics-13-03132" ref-type="bibr">5</xref>,<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>,<xref rid="B19-diagnostics-13-03132" ref-type="bibr">19</xref>]. In the group reported by Mathijssen et al., none of the patients with post-capillary SAPH had cardiac sarcoidosis, and all had preserved systolic LV function [<xref rid="B7-diagnostics-13-03132" ref-type="bibr">7</xref>]. In another study, 65% of post-capillary SAPH patients had normal LV ejection fraction, data on cardiac involvement were not reported. In that study, patients with post-capillary SAPH and impaired LV function were clinically indistinguishable from patients without LV disease but had better clinical outcomes [<xref rid="B24-diagnostics-13-03132" ref-type="bibr">24</xref>]. It is also interesting that no pulmonary hypertension was observed in a French cohort of cardiac sarcoidosis patients despite systolic or diastolic LV dysfunction in many of them [<xref rid="B109-diagnostics-13-03132" ref-type="bibr">109</xref>]. These data may undermine the theory of such a straightforward cause-and-effect relationship between post-capillary SAPH and cardiac sarcoidosis. An alternative explanation could include the known vast intrinsic and extrinsic involvement of pulmonary veins of all calibre in sarcoidosis [<xref rid="B4-diagnostics-13-03132" ref-type="bibr">4</xref>,<xref rid="B97-diagnostics-13-03132" ref-type="bibr">97</xref>,<xref rid="B100-diagnostics-13-03132" ref-type="bibr">100</xref>,<xref rid="B101-diagnostics-13-03132" ref-type="bibr">101</xref>,<xref rid="B102-diagnostics-13-03132" ref-type="bibr">102</xref>]. In the cohort of sarcoidosis patients listed for LTx, the PAWP was significantly higher in the group with PH compared to patients with no PH [<xref rid="B35-diagnostics-13-03132" ref-type="bibr">35</xref>]. Unfortunately, patients with post-capillary PH are often excluded from studies on SAPH [<xref rid="B5-diagnostics-13-03132" ref-type="bibr">5</xref>,<xref rid="B6-diagnostics-13-03132" ref-type="bibr">6</xref>,<xref rid="B8-diagnostics-13-03132" ref-type="bibr">8</xref>], and reports on cardiac sarcoidosis do notexplore this intriguing plot.</p><p>In post-capillary SAPH due to cardiac sarcoidosis, glucocorticoids and other immunosuppressive agents are recommended. In addition, the standard treatment for cardiac failure should be applied as appropriate [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>,<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>,<xref rid="B51-diagnostics-13-03132" ref-type="bibr">51</xref>]. This SAPH phenotype requires more attention in future studies.</p></sec><sec id="sec2dot5-diagnostics-13-03132"><title>2.5. Portal Hypertension</title><p>The liver involvement can be found in 50&#8211;75% of sarcoidosis patients, but symptomatic disease occurs in only 5&#8211;15% [<xref rid="B110-diagnostics-13-03132" ref-type="bibr">110</xref>,<xref rid="B111-diagnostics-13-03132" ref-type="bibr">111</xref>]. Portal hypertension (PoH) develops in less than 1% of sarcoidosis patients [<xref rid="B111-diagnostics-13-03132" ref-type="bibr">111</xref>] and in up to 33% of patients with proven hepatic sarcoidosis [<xref rid="B110-diagnostics-13-03132" ref-type="bibr">110</xref>]. PoH can be caused by biliary cirrhosis or the compression of the portal vein by involved lymph nodes or parenchymal granulomas, as well as sarcoid hepatic vasculitis [<xref rid="B110-diagnostics-13-03132" ref-type="bibr">110</xref>,<xref rid="B111-diagnostics-13-03132" ref-type="bibr">111</xref>]. It is believed that 2&#8211;6% of patients with portal hypertension of various aetiology develop pulmonary arterial hypertension, also called portopulmonary hypertension (PoPH) [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>]. The overall occurrence of PoPH in sarcoidosis seems very rare, but it should not be forgotten in a differential workup of SAPH.</p><p>Glucocorticoids and other immunosuppressive agents are recommended for PH caused by sarcoid liver disease [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. Pulmonary vasodilators should also be considered [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec3-diagnostics-13-03132"><title>3. Conclusions</title><p>The true prevalence of SAPH and the prevalence of its phenotypes based on predominant cause remain unknown. In the era of precise and personalised medicine, such phenotyping is recommended to lead the management. However, SAPH phenotyping is not a straightforward process. Apart from lacking criteria and gaps in knowledge, multiple phenotypes usually coexist and patients can switch between phenotypes during the course of sarcoidosis. Sarcoid pulmonary vasculopathy is probably the most under-recognised pathophysiological factor of SAPH development, and post-capillary phenotype seems the least studied. Whether genotypes play a role in SAPH development or SAPH phenotype needs further studies [<xref rid="B22-diagnostics-13-03132" ref-type="bibr">22</xref>,<xref rid="B112-diagnostics-13-03132" ref-type="bibr">112</xref>,<xref rid="B113-diagnostics-13-03132" ref-type="bibr">113</xref>]. The complexity and distinctive features of SAPH do not allow for the direct translation and adoption of the findings from research on PH belonging to other WHO groups.</p><p>A transthoracic echocardiogram (TTE) should be performed as an initial assessment in all sarcoidosis patients presenting features indicative of PH [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>,<xref rid="B114-diagnostics-13-03132" ref-type="bibr">114</xref>,<xref rid="B115-diagnostics-13-03132" ref-type="bibr">115</xref>]. RHC is recommended in patients with high TTE probability of PH, in patients with intermediate probability of PH and FVC &#8805; 50%pred, and in patients being considered for LTx [<xref rid="B10-diagnostics-13-03132" ref-type="bibr">10</xref>]. Given the current understanding of SAPH and available therapeutical options, the pivotal step in its management is the recognition of an ongoing inflammation warranting immunosuppressive treatment. <sup>18</sup>F-FDG-PET seems to be the most helpful tool to achieve this goal; however, it has not been validated and standardised in this indication. There is a large need for well-planned research projects to properly characterise the epidemiology and phenotypes of SAPH and to establish an evidence-based management for this condition. It is also very important to take sarcoidosis into the differential workup of PH, remembering that it may cause PH without visible involvement of the lungs or thoracic lymph nodes.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualisation, M.S. and A.K.; writing&#8212;original draft preparation, A.K.; writing&#8212;review and editing, M.S. and W.T.; supervision; M.S. and W.T. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-diagnostics-13-03132"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humbert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hoeper</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Badagliacca</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>R.M.F.</given-names></name><name name-style="western"><surname>Brida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coats</surname><given-names>A.J.S.</given-names></name><name name-style="western"><surname>Escribano-Subias</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>P.</given-names></name><etal/></person-group><article-title>2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension</article-title><source>Eur. Respir. J.</source><year>2023</year><volume>61</volume><fpage>2200879</fpage><pub-id pub-id-type="doi">10.1183/13993003.00879-2022</pub-id><pub-id pub-id-type="pmid">36028254</pub-id></element-citation></ref><ref id="B2-diagnostics-13-03132"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Chronic cor pulmonale. Report of an expert committee</article-title><source>World Health Organ. Tech. Rep. Ser.</source><year>1961</year><volume>213</volume><fpage>35</fpage><pub-id pub-id-type="pmid">14447583</pub-id></element-citation></ref><ref id="B3-diagnostics-13-03132"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sulica</surname><given-names>R.</given-names></name><name name-style="western"><surname>Teirstein</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kakarla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nemani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Behnegar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>M.L.</given-names></name></person-group><article-title>Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>1483</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1378/chest.128.3.1483</pub-id><pub-id pub-id-type="pmid">16162747</pub-id></element-citation></ref><ref id="B4-diagnostics-13-03132"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Humbert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Capron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brauner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sitbon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Battesti</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Simonneau</surname><given-names>G.</given-names></name><name name-style="western"><surname>Valeyre</surname><given-names>D.</given-names></name></person-group><article-title>Pulmonary hypertension associated with sarcoidosis: Mechanisms, haemodynamics and prognosis</article-title><source>Thorax</source><year>2006</year><volume>61</volume><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1136/thx.2005.042838</pub-id><pub-id pub-id-type="pmid">16227329</pub-id><pub-id pub-id-type="pmcid">PMC2080703</pub-id></element-citation></ref><ref id="B5-diagnostics-13-03132"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Shlobin</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Alhamad</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Culver</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Barney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cordova</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Carmona</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Scholand</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Wijsenbeek</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry</article-title><source>Respir. Med.</source><year>2018</year><volume>139</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2018.04.015</pub-id><pub-id pub-id-type="pmid">29858005</pub-id></element-citation></ref><ref id="B6-diagnostics-13-03132"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parikh</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Dahhan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nicholl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruopp</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pomann</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tapson</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Rajagopal</surname><given-names>S.</given-names></name></person-group><article-title>Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>4061</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-40030-w</pub-id><pub-id pub-id-type="pmid">30858405</pub-id><pub-id pub-id-type="pmcid">PMC6411962</pub-id></element-citation></ref><ref id="B7-diagnostics-13-03132"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathijssen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>A.L.M.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mager</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Grutters</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Post</surname><given-names>M.C.</given-names></name></person-group><article-title>Clinical Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension</article-title><source>Heart Lung Circ.</source><year>2021</year><volume>30</volume><fpage>1502</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1016/j.hlc.2021.03.279</pub-id><pub-id pub-id-type="pmid">33933365</pub-id></element-citation></ref><ref id="B8-diagnostics-13-03132"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boucly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cottin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ja&#239;s</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tazi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pr&#233;v&#244;t</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reynaud-Gaubert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dromer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Viacroze</surname><given-names>C.</given-names></name><name name-style="western"><surname>Horeau-Langlard</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension</article-title><source>Eur. Respir. J.</source><year>2017</year><volume>50</volume><fpage>1700465</fpage><pub-id pub-id-type="doi">10.1183/13993003.00465-2017</pub-id><pub-id pub-id-type="pmid">29051269</pub-id></element-citation></ref><ref id="B9-diagnostics-13-03132"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huitema</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>A.L.M.</given-names></name><name name-style="western"><surname>Mager</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Rensing</surname><given-names>B.J.W.M.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>F.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Grutters</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Post</surname><given-names>M.C.</given-names></name></person-group><article-title>Prevalence of pulmonary hypertension in pulmonary sarcoidosis: The first large European prospective study</article-title><source>Eur. Respir. J.</source><year>2019</year><volume>54</volume><fpage>1900897</fpage><pub-id pub-id-type="doi">10.1183/13993003.00897-2019</pub-id><pub-id pub-id-type="pmid">31320453</pub-id></element-citation></ref><ref id="B10-diagnostics-13-03132"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savale</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shlobin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kouranos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grutters</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Culver</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Post</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension</article-title><source>Eur. Respir. Rev.</source><year>2022</year><volume>31</volume><fpage>210165</fpage><pub-id pub-id-type="doi">10.1183/16000617.0165-2021</pub-id><pub-id pub-id-type="pmid">35140103</pub-id><pub-id pub-id-type="pmcid">PMC9489049</pub-id></element-citation></ref><ref id="B11-diagnostics-13-03132"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iannuzzi</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Rybicki</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Teirstein</surname><given-names>A.S.</given-names></name></person-group><article-title>Sarcoidosis</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>357</volume><fpage>2153</fpage><lpage>2165</lpage><pub-id pub-id-type="doi">10.1056/NEJMra071714</pub-id><pub-id pub-id-type="pmid">18032765</pub-id></element-citation></ref><ref id="B12-diagnostics-13-03132"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardinello</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petrarulo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Balestro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cocconcelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Veltkamp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spagnolo</surname><given-names>P.</given-names></name></person-group><article-title>Pulmonary Sarcoidosis: Diagnosis and Differential Diagnosis</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><elocation-id>1558</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics11091558</pub-id><pub-id pub-id-type="pmid">34573900</pub-id><pub-id pub-id-type="pmcid">PMC8472810</pub-id></element-citation></ref><ref id="B13-diagnostics-13-03132"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiosano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Versini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dar Antaki</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spitzer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yavne</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Watad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>O.</given-names></name><name name-style="western"><surname>Comaneshter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Amital</surname><given-names>H.</given-names></name></person-group><article-title>The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension&#8212;A cohort study</article-title><source>Clin. Immunol.</source><year>2019</year><volume>199</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2018.12.012</pub-id><pub-id pub-id-type="pmid">30543925</pub-id></element-citation></ref><ref id="B14-diagnostics-13-03132"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dahabra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abou Yassine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Assaad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>M.</given-names></name><name name-style="western"><surname>El-Sayegh</surname><given-names>D.</given-names></name></person-group><article-title>Association Between Sarcoidosis and Risk of Venous Thromboembolism: A Retrospective Chart Review</article-title><source>Cureus</source><year>2022</year><volume>14</volume><fpage>e25520</fpage><pub-id pub-id-type="doi">10.7759/cureus.25520</pub-id><pub-id pub-id-type="pmid">35800801</pub-id><pub-id pub-id-type="pmcid">PMC9245334</pub-id></element-citation></ref><ref id="B15-diagnostics-13-03132"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ungprasert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crowson</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>E.L.</given-names></name></person-group><article-title>Association of Sarcoidosis with Increased Risk of VTE: A Population-Based Study, 1976 to 2013</article-title><source>Chest</source><year>2017</year><volume>151</volume><fpage>425</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2016.09.009</pub-id><pub-id pub-id-type="pmid">27687848</pub-id><pub-id pub-id-type="pmcid">PMC5310113</pub-id></element-citation></ref><ref id="B16-diagnostics-13-03132"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mari</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Pasciuto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Siciliano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simonetti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ballacci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Macagno</surname><given-names>F.</given-names></name><name name-style="western"><surname>Iovene</surname><given-names>B.</given-names></name><name name-style="western"><surname>Martone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Corbo</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Richeldi</surname><given-names>L.</given-names></name></person-group><article-title>Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2020</year><volume>37</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.36141/svdld.v37i2.9169</pub-id><pub-id pub-id-type="pmcid">PMC7569553</pub-id><pub-id pub-id-type="pmid">33093780</pub-id></element-citation></ref><ref id="B17-diagnostics-13-03132"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito-Zer&#243;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kostov</surname><given-names>B.</given-names></name><name name-style="western"><surname>Superville</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ramos-Casals</surname><given-names>M.</given-names></name><collab>Autoimmune Big Data Study Group</collab></person-group><article-title>Geoepidemiological big data approach to sarcoidosis: Geographical and ethnic determinants</article-title><source>Clin. Exp. Rrheumatol.</source><year>2019</year><volume>37</volume><fpage>1052</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">31498063</pub-id></element-citation></ref><ref id="B18-diagnostics-13-03132"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name></person-group><article-title>Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis</article-title><source>Front. Cardiovasc. Med.</source><year>2022</year><volume>8</volume><fpage>809594</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.809594</pub-id><pub-id pub-id-type="pmid">35111830</pub-id><pub-id pub-id-type="pmcid">PMC8801498</pub-id></element-citation></ref><ref id="B19-diagnostics-13-03132"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shlobin</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Kouranos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Alhamad</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Culver</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Barney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cordova</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Carmona</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Scholand</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Wijsenbeek</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: Results from an international registry</article-title><source>Eur. Respir. J.</source><year>2020</year><volume>55</volume><fpage>1901747</fpage><pub-id pub-id-type="doi">10.1183/13993003.01747-2019</pub-id><pub-id pub-id-type="pmid">32139456</pub-id></element-citation></ref><ref id="B20-diagnostics-13-03132"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maron</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Brittain</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>E.</given-names></name><name name-style="western"><surname>Waldo</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Bar&#243;n</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Assad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wertheim</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Alba</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: A retrospective cohort study</article-title><source>Lancet Respir. Med.</source><year>2020</year><volume>8</volume><fpage>873</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30317-9</pub-id><pub-id pub-id-type="pmid">32730752</pub-id><pub-id pub-id-type="pmcid">PMC8219057</pub-id></element-citation></ref><ref id="B21-diagnostics-13-03132"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#322;uskowski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hawry&#322;kiewicz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zych</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wojtczak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zieli&#324;ski</surname><given-names>J.</given-names></name></person-group><article-title>Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis</article-title><source>Respiration</source><year>1984</year><volume>46</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1159/000194667</pub-id><pub-id pub-id-type="pmid">6494605</pub-id></element-citation></ref><ref id="B22-diagnostics-13-03132"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>van der Vis</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Post</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Grutters</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>van Moorsel</surname><given-names>C.H.M.</given-names></name></person-group><article-title>Pulmonary Hypertension Associated Genetic Variants in Sarcoidosis Associated Pulmonary Hypertension</article-title><source>Diagnostics</source><year>2022</year><volume>12</volume><elocation-id>2564</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics12102564</pub-id><pub-id pub-id-type="pmid">36292254</pub-id><pub-id pub-id-type="pmcid">PMC9601358</pub-id></element-citation></ref><ref id="B23-diagnostics-13-03132"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkil</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lower</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name></person-group><article-title>Predictors of mortality in pulmonary sarcoidosis</article-title><source>Chest</source><year>2018</year><volume>153</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2017.07.008</pub-id><pub-id pub-id-type="pmid">28728933</pub-id></element-citation></ref><ref id="B24-diagnostics-13-03132"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lower</surname><given-names>E.E.</given-names></name></person-group><article-title>Survival in sarcoidosis-associated pulmonary hypertension: The importance of hemodynamic evaluation</article-title><source>Chest</source><year>2010</year><volume>138</volume><fpage>1078</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1378/chest.09-2002</pub-id><pub-id pub-id-type="pmid">20348196</pub-id></element-citation></ref><ref id="B25-diagnostics-13-03132"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huitema</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>A.L.M.</given-names></name><name name-style="western"><surname>Mager</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>van Houten</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grutters</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Post</surname><given-names>M.C.</given-names></name></person-group><article-title>Four-year survival rate in pulmonary sarcoidosis with extensive pulmonary hypertension screening</article-title><source>Respir. Med.</source><year>2022</year><volume>195</volume><fpage>106762</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2022.106762</pub-id><pub-id pub-id-type="pmid">35227546</pub-id></element-citation></ref><ref id="B26-diagnostics-13-03132"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeny</surname><given-names>F.</given-names></name><name name-style="western"><surname>Uzunhan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lacroix</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gille</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brillet</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Nardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bouvry</surname><given-names>D.</given-names></name><name name-style="western"><surname>Plan&#232;s</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Valeyre</surname><given-names>D.</given-names></name></person-group><article-title>Predictors of mortality in fibrosing pulmonary sarcoidosis</article-title><source>Respir. Med.</source><year>2020</year><volume>169</volume><fpage>105997</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2020.105997</pub-id><pub-id pub-id-type="pmid">32442108</pub-id></element-citation></ref><ref id="B27-diagnostics-13-03132"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>U.</given-names></name></person-group><article-title>Mortality and Morbidity of Pulmonary Hypertension amongst Patients with Sarcoidosis&#8212;A Nationwide Study</article-title><source>J. Am. Coll. Cardiol.</source><year>2023</year><volume>81</volume><fpage>1913</fpage><pub-id pub-id-type="doi">10.1016/S0735-1097(23)02357-4</pub-id></element-citation></ref><ref id="B28-diagnostics-13-03132"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schimmelpennink</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Meek</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Vorselaars</surname><given-names>A.D.M.</given-names></name><name name-style="western"><surname>Langezaal</surname><given-names>L.C.M.</given-names></name><name name-style="western"><surname>van Moorsel</surname><given-names>C.H.M.</given-names></name><name name-style="western"><surname>van der Vis</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Veltkamp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grutters</surname><given-names>J.C.</given-names></name></person-group><article-title>Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis</article-title><source>Respir. Res.</source><year>2022</year><volume>23</volume><fpage>169</fpage><pub-id pub-id-type="doi">10.1186/s12931-022-02094-7</pub-id><pub-id pub-id-type="pmid">35752806</pub-id><pub-id pub-id-type="pmcid">PMC9233403</pub-id></element-citation></ref><ref id="B29-diagnostics-13-03132"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonham</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Oldham</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gomberg-Maitland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vij</surname><given-names>R.</given-names></name></person-group><article-title>Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: A retrospective case series</article-title><source>Chest</source><year>2015</year><volume>148</volume><fpage>1055</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1378/chest.14-2546</pub-id><pub-id pub-id-type="pmid">26437815</pub-id><pub-id pub-id-type="pmcid">PMC4594624</pub-id></element-citation></ref><ref id="B30-diagnostics-13-03132"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobarro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Handler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beynon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Denton</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Coghlan</surname><given-names>J.G.</given-names></name></person-group><article-title>Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data</article-title><source>Am. J. Cardiol.</source><year>2013</year><volume>111</volume><fpage>278</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2012.09.031</pub-id><pub-id pub-id-type="pmid">23290599</pub-id></element-citation></ref><ref id="B31-diagnostics-13-03132"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thillai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Crawshaw</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Kouranos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Screaton</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Whight</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.U.</given-names></name></person-group><article-title>BTS Clinical Statement on pulmonary sarcoidosis</article-title><source>Thorax</source><year>2021</year><volume>76</volume><fpage>4</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2019-214348</pub-id><pub-id pub-id-type="pmid">33268456</pub-id></element-citation></ref><ref id="B32-diagnostics-13-03132"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sofia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Richeldi</surname><given-names>L.</given-names></name></person-group><article-title>Novel insights in fibrotic pulmonary sarcoidosis</article-title><source>Curr. Opin. Pulm. Med.</source><year>2022</year><volume>28</volume><fpage>478</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1097/MCP.0000000000000893</pub-id><pub-id pub-id-type="pmid">35838359</pub-id></element-citation></ref><ref id="B33-diagnostics-13-03132"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costabel</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hunninghake</surname><given-names>G.W.</given-names></name></person-group><article-title>ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders</article-title><source>Eur. Respir. J.</source><year>1999</year><volume>14</volume><fpage>735</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3003.1999.14d02.x</pub-id><pub-id pub-id-type="pmid">10573213</pub-id></element-citation></ref><ref id="B34-diagnostics-13-03132"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Prevalence and Epidemiology of Pulmonary Hypertension Amongst Patients with Sarcoidosis</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2023</year><volume>207</volume><fpage>A3289</fpage></element-citation></ref><ref id="B35-diagnostics-13-03132"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shorr</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Helman</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name></person-group><article-title>Pulmonary hypertension in advanced sarcoidosis: Epidemiology and clinical characteristics</article-title><source>Eur. Respir. J.</source><year>2005</year><volume>25</volume><fpage>783</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1183/09031936.05.00083404</pub-id><pub-id pub-id-type="pmid">15863633</pub-id></element-citation></ref><ref id="B36-diagnostics-13-03132"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seeger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Adir</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Barber&#224;</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Champion</surname><given-names>H.</given-names></name><name name-style="western"><surname>Coghlan</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Cottin</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gali&#232;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Pulmonary hypertension in chronic lung diseases</article-title><source>J. Am. Coll. Cardiol.</source><year>2013</year><volume>62</volume><fpage>D109</fpage><lpage>D116</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.10.036</pub-id><pub-id pub-id-type="pmid">24355635</pub-id></element-citation></ref><ref id="B37-diagnostics-13-03132"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Barbera</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gaine</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Harari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Olschewski</surname><given-names>H.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Pepke-Zaba</surname><given-names>J.</given-names></name><name name-style="western"><surname>Provencher</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Pulmonary hypertension in chronic lung disease and hypoxia</article-title><source>Eur. Respir. J.</source><year>2019</year><volume>53</volume><fpage>1801916</fpage><pub-id pub-id-type="doi">10.1183/13993003.01914-2018</pub-id><pub-id pub-id-type="pmid">30545980</pub-id><pub-id pub-id-type="pmcid">PMC6351338</pub-id></element-citation></ref><ref id="B38-diagnostics-13-03132"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tatsumi</surname><given-names>K.</given-names></name></person-group><article-title>Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis</article-title><source>J. Am. Heart Assoc.</source><year>2019</year><volume>8</volume><fpage>e013310</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.013310</pub-id><pub-id pub-id-type="pmid">31423872</pub-id><pub-id pub-id-type="pmcid">PMC6759907</pub-id></element-citation></ref><ref id="B39-diagnostics-13-03132"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taraseviciene-Stewart</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cool</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Voelkel</surname><given-names>N.F.</given-names></name></person-group><article-title>Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells</article-title><source>FASEB J.</source><year>2005</year><volume>19</volume><fpage>1178</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1096/fj.04-3261fje</pub-id><pub-id pub-id-type="pmid">15897232</pub-id></element-citation></ref><ref id="B40-diagnostics-13-03132"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruffenach</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vaillancourt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Medzikovic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eghbali</surname><given-names>M.</given-names></name></person-group><article-title>Pulmonary hypertension secondary to pulmonary fibrosis: Clinical data, histopathology and molecular insights</article-title><source>Respir. Res.</source><year>2020</year><volume>21</volume><fpage>303</fpage><pub-id pub-id-type="doi">10.1186/s12931-020-01570-2</pub-id><pub-id pub-id-type="pmid">33208169</pub-id><pub-id pub-id-type="pmcid">PMC7677848</pub-id></element-citation></ref><ref id="B41-diagnostics-13-03132"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Hosokawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Babicheva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pourhashemi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Balistrieri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Revisiting the mechanism of hypoxic pulmonary vasoconstriction using isolated perfused/ventilated mouse lung</article-title><source>Pulm. Circ.</source><year>2020</year><volume>10</volume><fpage>2045894020956592</fpage><pub-id pub-id-type="doi">10.1177/2045894020956592</pub-id><pub-id pub-id-type="pmid">33282184</pub-id><pub-id pub-id-type="pmcid">PMC7691930</pub-id></element-citation></ref><ref id="B42-diagnostics-13-03132"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humbert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guignabert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dorfm&#252;ller</surname><given-names>P.</given-names></name><name name-style="western"><surname>Klinger</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Nicolls</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Olschewski</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Pullamsetti</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Schermuly</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Stenmark</surname><given-names>K.R.</given-names></name><etal/></person-group><article-title>Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives</article-title><source>Eur. Respir. J.</source><year>2018</year><volume>53</volume><fpage>1801887</fpage><pub-id pub-id-type="doi">10.1183/13993003.01887-2018</pub-id><pub-id pub-id-type="pmcid">PMC6351340</pub-id><pub-id pub-id-type="pmid">30545970</pub-id></element-citation></ref><ref id="B43-diagnostics-13-03132"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaikwad</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhattarai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Larby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haug</surname><given-names>G.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jaffar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Westall</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Vascular remodelling in idiopathic pulmonary fibrosis patients and its detrimental effect on lung physiology: Potential role of endothelial-to-mesenchymal transition</article-title><source>ERJ Open Res.</source><year>2022</year><volume>8</volume><fpage>00571</fpage><lpage>02021</lpage><pub-id pub-id-type="doi">10.1183/23120541.00571-2021</pub-id><pub-id pub-id-type="pmid">35350273</pub-id><pub-id pub-id-type="pmcid">PMC8943284</pub-id></element-citation></ref><ref id="B44-diagnostics-13-03132"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dotan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gangemi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aneja</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dass</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>N.</given-names></name><name name-style="western"><surname>D&#8217;Alonzo</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Pulmonary vasculopathy in explanted lungs from patients with interstitial lung disease undergoing lung transplantation</article-title><source>BMJ Open Respir. Res.</source><year>2020</year><volume>7</volume><fpage>e000532</fpage><pub-id pub-id-type="doi">10.1136/bmjresp-2019-000532</pub-id><pub-id pub-id-type="pmcid">PMC7359183</pub-id><pub-id pub-id-type="pmid">32661103</pub-id></element-citation></ref><ref id="B45-diagnostics-13-03132"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sugino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uekusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takemura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Homma</surname><given-names>S.</given-names></name></person-group><article-title>An autopsy case of refractory pulmonary hypertension with sarcoidosis</article-title><source>Respir. Investig.</source><year>2016</year><volume>54</volume><fpage>490</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1016/j.resinv.2016.05.005</pub-id><pub-id pub-id-type="pmid">27886864</pub-id></element-citation></ref><ref id="B46-diagnostics-13-03132"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Lescure</surname><given-names>T.</given-names></name><name name-style="western"><surname>Robson</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sartori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Narula</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vergani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Soultanidis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morgenthau</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pulmonary Artery <sup>18</sup>F-Fluorodeoxyglucose Uptake by PET/CMR as a Marker of Pulmonary Hypertension in Sarcoidosis</article-title><source>JACC Cardiovasc. Imaging</source><year>2022</year><volume>15</volume><fpage>108</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2021.05.023</pub-id><pub-id pub-id-type="pmid">34274283</pub-id></element-citation></ref><ref id="B47-diagnostics-13-03132"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ovadia</surname><given-names>M.</given-names></name></person-group><article-title>Pulmonary Arterial <sup>18</sup>F-FDG Uptake in Sarcoidosis: A Novel Biosignal for Subclinical Pulmonary Hypertension</article-title><source>JACC Cardiovasc. Imaging</source><year>2022</year><volume>15</volume><fpage>121</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2021.08.014</pub-id><pub-id pub-id-type="pmid">34801464</pub-id></element-citation></ref><ref id="B48-diagnostics-13-03132"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shorr</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name></person-group><article-title>Outcomes for patients with sarcoidosis awaiting lung transplantation</article-title><source>Chest</source><year>2002</year><volume>122</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1378/chest.122.1.233</pub-id><pub-id pub-id-type="pmid">12114364</pub-id></element-citation></ref><ref id="B49-diagnostics-13-03132"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bax</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bredy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kempny</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Devaraj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kokosi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keir</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease</article-title><source>ERJ Open Res.</source><year>2018</year><volume>4</volume><fpage>00124</fpage><lpage>02017</lpage><pub-id pub-id-type="doi">10.1183/23120541.00124-2017</pub-id><pub-id pub-id-type="pmcid">PMC5934528</pub-id><pub-id pub-id-type="pmid">29750141</pub-id></element-citation></ref><ref id="B50-diagnostics-13-03132"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamada</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hontsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pulmonary sarcoidosis with a cavitary lesion in the lung caused by a TNF-&#945; inhibitor: A case report</article-title><source>Respirol. Case Rep.</source><year>2022</year><volume>10</volume><fpage>e01065</fpage><pub-id pub-id-type="doi">10.1002/rcr2.1065</pub-id><pub-id pub-id-type="pmid">36415783</pub-id><pub-id pub-id-type="pmcid">PMC9673597</pub-id></element-citation></ref><ref id="B51-diagnostics-13-03132"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Valeyre</surname><given-names>D.</given-names></name><name name-style="western"><surname>Korsten</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mathioudakis</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Wuyts</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rottoli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lower</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Judson</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>ERS clinical practice guidelines on treatment of sarcoidosis</article-title><source>Eur. Respir. J.</source><year>2021</year><volume>58</volume><fpage>2004079</fpage><pub-id pub-id-type="doi">10.1183/13993003.04079-2020</pub-id><pub-id pub-id-type="pmid">34140301</pub-id></element-citation></ref><ref id="B52-diagnostics-13-03132"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahaghi</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Saketkoo</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Sweiss</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Barney</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Birring</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Costabel</surname><given-names>U.</given-names></name><name name-style="western"><surname>Crouser</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Drent</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gerke</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis</article-title><source>Eur. Rrespir. Rev.</source><year>2020</year><volume>29</volume><fpage>190146</fpage><pub-id pub-id-type="doi">10.1183/16000617.0146-2019</pub-id><pub-id pub-id-type="pmid">32198218</pub-id><pub-id pub-id-type="pmcid">PMC9488897</pub-id></element-citation></ref><ref id="B53-diagnostics-13-03132"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Shlobin</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Lower</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Rahaghi</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Zeigler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name></person-group><article-title>Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial</article-title><source>Chest</source><year>2022</year><volume>161</volume><fpage>448</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2021.07.2162</pub-id><pub-id pub-id-type="pmid">34363816</pub-id><pub-id pub-id-type="pmcid">PMC9005858</pub-id></element-citation></ref><ref id="B54-diagnostics-13-03132"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma&#241;&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rubio-Rivas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villalba</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marcoval</surname><given-names>J.</given-names></name><name name-style="western"><surname>Iriarte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Molina-Molina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Llatjos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Y&#233;lamos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vicens-Zygmunt</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain</article-title><source>Medicine</source><year>2017</year><volume>96</volume><fpage>e7595</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000007595</pub-id><pub-id pub-id-type="pmid">28723801</pub-id><pub-id pub-id-type="pmcid">PMC5521941</pub-id></element-citation></ref><ref id="B55-diagnostics-13-03132"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>J.L.</given-names></name></person-group><article-title>Histopathology of Explanted Lungs from Patients with a Diagnosis of Pulmonary Sarcoidosis</article-title><source>Chest</source><year>2016</year><volume>149</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1378/chest.15-0615</pub-id><pub-id pub-id-type="pmid">26158549</pub-id></element-citation></ref><ref id="B56-diagnostics-13-03132"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kligerman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>A.</given-names></name></person-group><article-title>End-stage sarcoid lung disease is distinct from usual interstitial pneumonia</article-title><source>Am. J. Surg. Pathol.</source><year>2013</year><volume>37</volume><fpage>593</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e3182785a2d</pub-id><pub-id pub-id-type="pmid">23426125</pub-id></element-citation></ref><ref id="B57-diagnostics-13-03132"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Rooij</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Moorsel</surname><given-names>C.H.M.</given-names></name><name name-style="western"><surname>Spee-Dropkova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grutters</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Keijsers</surname><given-names>R.G.</given-names></name></person-group><article-title>Volumetric FDG PET analysis of global lung inflammation: New tool for precision medicine in pulmonary sarcoidosis?</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2018</year><volume>35</volume><fpage>44</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.36141/svdld.v35i1.5807</pub-id><pub-id pub-id-type="pmcid">PMC7170065</pub-id><pub-id pub-id-type="pmid">32476879</pub-id></element-citation></ref><ref id="B58-diagnostics-13-03132"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schimmelpennink</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Vorselaars</surname><given-names>A.D.M.</given-names></name><name name-style="western"><surname>Veltkamp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keijsers</surname><given-names>R.G.M.</given-names></name></person-group><article-title>Quantification of pulmonary disease activity in sarcoidosis measured with <sup>18</sup>F-FDG PET/CT: SUVmax versus total lung glycolysis</article-title><source>EJNMMI Res.</source><year>2019</year><volume>9</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s13550-019-0505-x</pub-id><pub-id pub-id-type="pmid">31197630</pub-id><pub-id pub-id-type="pmcid">PMC6565791</pub-id></element-citation></ref><ref id="B59-diagnostics-13-03132"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mostard</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Verschakelen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>van Kroonenburgh</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Nelemans</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Wijnen</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>V&#246;&#246;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Drent</surname><given-names>M.</given-names></name></person-group><article-title>Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis</article-title><source>Respir. Med.</source><year>2013</year><volume>107</volume><fpage>439</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2012.11.011</pub-id><pub-id pub-id-type="pmid">23261309</pub-id></element-citation></ref><ref id="B60-diagnostics-13-03132"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uzunhan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gille</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lamberto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Valeyre</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brillet</surname><given-names>P.Y.</given-names></name></person-group><article-title>Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function</article-title><source>Eur. Respir. J.</source><year>2012</year><volume>40</volume><fpage>750</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1183/09031936.00025212</pub-id><pub-id pub-id-type="pmid">22790910</pub-id></element-citation></ref><ref id="B61-diagnostics-13-03132"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaikh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abtin</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saggar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Belperio</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>J.P.</given-names><suffix>III</suffix></name></person-group><article-title>Radiographic and Histopathologic Features in Sarcoidosis: A Pictorial Display</article-title><source>Semin. Respir. Crit. Care Med.</source><year>2020</year><volume>41</volume><fpage>758</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1055/s-0040-1712534</pub-id><pub-id pub-id-type="pmid">32777856</pub-id></element-citation></ref><ref id="B62-diagnostics-13-03132"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vagts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ascoli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fraidenburg</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Edafetanure-Ibeh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><fpage>595077</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.595077</pub-id><pub-id pub-id-type="pmid">33718397</pub-id><pub-id pub-id-type="pmcid">PMC7943443</pub-id></element-citation></ref><ref id="B63-diagnostics-13-03132"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popevi&#263;</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#352;umarac</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jovanovi&#263;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Babi&#263;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stjepanovi&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jovi&#269;i&#263;</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#352;obi&#263;-&#352;aranovi&#263;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Filipovi&#263;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gvozdenovi&#263;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Om&#269;ikus</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Verifying Sarcoidosis Activity: Chitotriosidase versus ACE in Sarcoidosis&#8212;A Case-control Study</article-title><source>J. Med. Biochem.</source><year>2016</year><volume>35</volume><fpage>390</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1515/jomb-2016-0017</pub-id><pub-id pub-id-type="pmid">28670191</pub-id><pub-id pub-id-type="pmcid">PMC5471634</pub-id></element-citation></ref><ref id="B64-diagnostics-13-03132"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le&#353;tan Ramov&#353;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sodin-&#352;emrl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lakota</surname><given-names>K.</given-names></name><name name-style="western"><surname>&#268;u&#269;nik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manevski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zba&#269;nik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zupan&#269;i&#269;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verbi&#269;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ter&#269;elj</surname><given-names>M.</given-names></name></person-group><article-title>Correlation of the High-Resolution Computed Tomography Patterns of Intrathoracic Sarcoidosis with Serum Levels of SAA, CA 15.3, SP-D, and Other Biomarkers of Interstitial Lung Disease</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>10794</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241310794</pub-id><pub-id pub-id-type="pmid">37445972</pub-id><pub-id pub-id-type="pmcid">PMC10341825</pub-id></element-citation></ref><ref id="B65-diagnostics-13-03132"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraaijvanger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Janssen Bon&#225;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vorselaars</surname><given-names>A.D.M.</given-names></name><name name-style="western"><surname>Veltkamp</surname><given-names>M.</given-names></name></person-group><article-title>Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1443</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01443</pub-id><pub-id pub-id-type="pmid">32760396</pub-id><pub-id pub-id-type="pmcid">PMC7372102</pub-id></element-citation></ref><ref id="B66-diagnostics-13-03132"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flaherty</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Cottin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Devaraj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.L.F.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Richeldi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stowasser</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Nintedanib in Progressive Fibrosing Interstitial Lung Diseases</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>1718</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1908681</pub-id><pub-id pub-id-type="pmid">31566307</pub-id></element-citation></ref><ref id="B67-diagnostics-13-03132"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Devaraj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Richeldi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crestani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wuyts</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Stowasser</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial</article-title><source>Lancet Respir. Med.</source><year>2020</year><volume>8</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30036-9</pub-id><pub-id pub-id-type="pmid">32145830</pub-id></element-citation></ref><ref id="B68-diagnostics-13-03132"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghazipura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mammen</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Hon</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bissell</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Macrea</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kheir</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khor</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Raghu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis</article-title><source>Ann. Am. Thorac. Soc.</source><year>2022</year><volume>19</volume><fpage>1040</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1513/AnnalsATS.202103-343OC</pub-id><pub-id pub-id-type="pmid">35499854</pub-id></element-citation></ref><ref id="B69-diagnostics-13-03132"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behr</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prasse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kreuter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Bonella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grohe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Held</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilkens</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial</article-title><source>Lancet Respir. Med.</source><year>2021</year><volume>9</volume><fpage>476</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30554-3</pub-id><pub-id pub-id-type="pmid">33798455</pub-id></element-citation></ref><ref id="B70-diagnostics-13-03132"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Judson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lower</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Birring</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.U.</given-names></name></person-group><article-title>Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: Results of a prospective feasibility study</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2022</year><volume>39</volume><fpage>e2022011</fpage><pub-id pub-id-type="doi">10.36141/svdld.v39i2.12940</pub-id><pub-id pub-id-type="pmcid">PMC9437762</pub-id><pub-id pub-id-type="pmid">36118538</pub-id></element-citation></ref><ref id="B71-diagnostics-13-03132"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hambly</surname><given-names>N.</given-names></name><name name-style="western"><surname>Farooqi</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Dvorkin-Gheva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donohoe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Garlick</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scallan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>MacIsaac</surname><given-names>S.</given-names></name><name name-style="western"><surname>Assayag</surname><given-names>D.</given-names></name><name name-style="western"><surname>Johannson</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry</article-title><source>Eur. Respir. J.</source><year>2022</year><volume>60</volume><fpage>2102571</fpage><pub-id pub-id-type="doi">10.1183/13993003.02571-2021</pub-id><pub-id pub-id-type="pmid">35273032</pub-id></element-citation></ref><ref id="B72-diagnostics-13-03132"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nashatyreva</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Trofimenko</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Chernyak</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Avdeev</surname><given-names>S.N.</given-names></name></person-group><article-title>Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia</article-title><source>Life</source><year>2023</year><volume>13</volume><elocation-id>212</elocation-id><pub-id pub-id-type="doi">10.3390/life13010212</pub-id><pub-id pub-id-type="pmid">36676161</pub-id><pub-id pub-id-type="pmcid">PMC9861544</pub-id></element-citation></ref><ref id="B73-diagnostics-13-03132"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niitsu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukushima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Komukai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwakoshi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shiroyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease</article-title><source>RMD Open</source><year>2023</year><volume>9</volume><fpage>e002667</fpage><pub-id pub-id-type="doi">10.1136/rmdopen-2022-002667</pub-id><pub-id pub-id-type="pmid">36690385</pub-id><pub-id pub-id-type="pmcid">PMC9872509</pub-id></element-citation></ref><ref id="B74-diagnostics-13-03132"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergantini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nardelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>d&#8217;Alessandro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montuori</surname><given-names>G.</given-names></name><name name-style="western"><surname>Piccioli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rosi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gangi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cavallaro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cameli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bargagli</surname><given-names>E.</given-names></name></person-group><article-title>Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): A New Phenotype or a Fortuitous Overlap? Scoping Review and Case Series</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>2065</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11072065</pub-id><pub-id pub-id-type="pmid">35407673</pub-id><pub-id pub-id-type="pmcid">PMC8999728</pub-id></element-citation></ref><ref id="B75-diagnostics-13-03132"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamp</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Neubert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stark</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hinrichs</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Boekhoff</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Ius</surname><given-names>F.</given-names></name><name name-style="western"><surname>Haverich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>J.</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>664</elocation-id><pub-id pub-id-type="doi">10.3390/cells11040664</pub-id><pub-id pub-id-type="pmid">35203313</pub-id><pub-id pub-id-type="pmcid">PMC8870272</pub-id></element-citation></ref><ref id="B76-diagnostics-13-03132"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Glassberg</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Raghu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Swigris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ettinger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Loyd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gillies</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated with Pulmonary Fibrosis</article-title><source>Chest</source><year>2020</year><volume>158</volume><fpage>637</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2020.02.016</pub-id><pub-id pub-id-type="pmid">32092321</pub-id></element-citation></ref><ref id="B77-diagnostics-13-03132"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waxman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Restrepo-Jaramillo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thenappan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bajwa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Argula</surname><given-names>R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2008470</pub-id><pub-id pub-id-type="pmid">33440084</pub-id></element-citation></ref><ref id="B78-diagnostics-13-03132"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Bach</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Yow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Toews</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Anstrom</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>F.J.</given-names></name><collab>IPFnet Investigators</collab></person-group><article-title>Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction</article-title><source>Chest</source><year>2013</year><volume>143</volume><fpage>1699</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1378/chest.12-1594</pub-id><pub-id pub-id-type="pmid">23732584</pub-id><pub-id pub-id-type="pmcid">PMC3673665</pub-id></element-citation></ref><ref id="B79-diagnostics-13-03132"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kacprzak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szturmowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burakowska</surname><given-names>B.</given-names></name><name name-style="western"><surname>Franczuk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kober</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kurzyna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szmit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Torbicki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ku&#347;</surname><given-names>J.</given-names></name></person-group><article-title>Sarcoidosis-associated pulmonary hypertension treated with sildenafil</article-title><source>Adv. Respir. Med.</source><year>2017</year><volume>85</volume><fpage>258</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.5603/ARM.a2017.0043</pub-id><pub-id pub-id-type="pmid">29083021</pub-id></element-citation></ref><ref id="B80-diagnostics-13-03132"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Iversen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Videbaek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>J.</given-names></name></person-group><article-title>Pulmonary hypertension in end-stage pulmonary sarcoidosis: Therapeutic effect of sildenafil?</article-title><source>J. Heart Lung Transplant.</source><year>2008</year><volume>27</volume><fpage>329</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2007.11.576</pub-id><pub-id pub-id-type="pmid">18342757</pub-id></element-citation></ref><ref id="B81-diagnostics-13-03132"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keir</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Gatzoulis</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raposeiras-Roubin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Renzoni</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Maher</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.U.</given-names></name><etal/></person-group><article-title>Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2014</year><volume>31</volume><fpage>82</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">25078636</pub-id></element-citation></ref><ref id="B82-diagnostics-13-03132"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathijssen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>A.L.M.</given-names></name><name name-style="western"><surname>Mager</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Grutters</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Post</surname><given-names>M.C.</given-names></name></person-group><article-title>Safety of macitentan in sarcoidosis-associated pulmonary hypertension: A case-series</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2020</year><volume>37</volume><fpage>74</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.36141/svdld.v37i1.9292</pub-id><pub-id pub-id-type="pmcid">PMC7569544</pub-id><pub-id pub-id-type="pmid">33093771</pub-id></element-citation></ref><ref id="B83-diagnostics-13-03132"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abston</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Govender</surname><given-names>P.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>H.W.</given-names></name></person-group><article-title>Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2020</year><volume>37</volume><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.36141/svdld.v37i2.9343</pub-id><pub-id pub-id-type="pmcid">PMC7569547</pub-id><pub-id pub-id-type="pmid">33093789</pub-id></element-citation></ref><ref id="B84-diagnostics-13-03132"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abston</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moll</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Govender</surname><given-names>P.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>H.</given-names></name></person-group><article-title>Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2020</year><volume>37</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.36141/svdld.v37i2.9150</pub-id><pub-id pub-id-type="pmcid">PMC7569545</pub-id><pub-id pub-id-type="pmid">33093782</pub-id></element-citation></ref><ref id="B85-diagnostics-13-03132"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Serlin</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>H.W.</given-names></name></person-group><article-title>Sarcoidosis-associated pulmonary hypertension: Outcome with long-term epoprostenol treatment</article-title><source>Chest</source><year>2006</year><volume>130</volume><fpage>1481</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1378/chest.130.5.1481</pub-id><pub-id pub-id-type="pmid">17099027</pub-id></element-citation></ref><ref id="B86-diagnostics-13-03132"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Bonura</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shlobin</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Osei</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zaiman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Hassoun</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Moller</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience</article-title><source>Chest</source><year>2009</year><volume>135</volume><fpage>1455</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1378/chest.08-1881</pub-id><pub-id pub-id-type="pmid">19118270</pub-id><pub-id pub-id-type="pmcid">PMC2821289</pub-id></element-citation></ref><ref id="B87-diagnostics-13-03132"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Judson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lower</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Highland</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>N.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>P.J.</given-names></name></person-group><article-title>Inhaled iloprost for sarcoidosis associated pulmonary hypertension</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2009</year><volume>26</volume><fpage>110</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">20560291</pub-id></element-citation></ref><ref id="B88-diagnostics-13-03132"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Judson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Highland</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Aris</surname><given-names>R.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>N.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>H.J.</given-names></name></person-group><article-title>Ambrisentan for sarcoidosis associated pulmonary hypertension</article-title><source>Sarcoidosis Vasc. Diffus. Lung Dis.</source><year>2011</year><volume>28</volume><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">22117505</pub-id></element-citation></ref><ref id="B89-diagnostics-13-03132"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ford</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Aris</surname><given-names>R.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>J.F.</given-names></name></person-group><article-title>Tadalafil therapy for sarcoidosis-associated pulmonary hypertension</article-title><source>Pulm. Circ.</source><year>2016</year><volume>6</volume><fpage>557</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1086/688775</pub-id><pub-id pub-id-type="pmid">28090299</pub-id><pub-id pub-id-type="pmcid">PMC5210066</pub-id></element-citation></ref><ref id="B90-diagnostics-13-03132"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baughman</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Culver</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cordova</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Lower</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>P.J.</given-names></name></person-group><article-title>Bosentan for sarcoidosis-associated pulmonary hypertension: A double-blind placebo controlled randomized trial</article-title><source>Chest</source><year>2014</year><volume>145</volume><fpage>810</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1378/chest.13-1766</pub-id><pub-id pub-id-type="pmid">24177203</pub-id></element-citation></ref><ref id="B91-diagnostics-13-03132"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Orfanos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lambers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Flaherty</surname><given-names>K.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>L.</given-names></name><name name-style="western"><surname>Silverstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name></person-group><article-title>The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD</article-title><source>Adv. Ther.</source><year>2022</year><volume>39</volume><fpage>3881</fpage><lpage>3895</lpage><pub-id pub-id-type="doi">10.1007/s12325-022-02229-8</pub-id><pub-id pub-id-type="pmid">35781186</pub-id><pub-id pub-id-type="pmcid">PMC9402520</pub-id></element-citation></ref><ref id="B92-diagnostics-13-03132"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nathan</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Waxman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rajagopal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Case</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johri</surname><given-names>S.</given-names></name><name name-style="western"><surname>DuBrock</surname><given-names>H.</given-names></name><name name-style="western"><surname>De La Zerda</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Sahay</surname><given-names>S.</given-names></name><name name-style="western"><surname>King</surname><given-names>C.</given-names></name><name name-style="western"><surname>Melendres-Groves</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: A post-hoc analysis of the INCREASE study</article-title><source>Lancet Respir. Med.</source><year>2021</year><volume>9</volume><fpage>1266</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00165-X</pub-id><pub-id pub-id-type="pmid">34214475</pub-id></element-citation></ref><ref id="B93-diagnostics-13-03132"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gayen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lashari</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Criner</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>James Mamary</surname><given-names>A.</given-names></name></person-group><article-title>Pulmonary vasodilator therapy in sarcoidosis-associated pulmonary hypertension may decrease lung function decline and mortality</article-title><source>Pulm. Circ.</source><year>2023</year><volume>5</volume><fpage>e12245</fpage><pub-id pub-id-type="doi">10.1002/pul2.12245</pub-id><pub-id pub-id-type="pmcid">PMC10241350</pub-id><pub-id pub-id-type="pmid">37284520</pub-id></element-citation></ref><ref id="B94-diagnostics-13-03132"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hostettler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baty</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kleiner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Junker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tamm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brutsche</surname><given-names>M.</given-names></name></person-group><article-title>Bosentan for patients with steroid-resistant pulmonary sarcoidosis: A randomised controlled trial</article-title><source>Swiss. Med. Wkly.</source><year>2018</year><volume>148</volume><fpage>w14677</fpage><pub-id pub-id-type="doi">10.4414/smw.2018.14677</pub-id><pub-id pub-id-type="pmid">30378090</pub-id></element-citation></ref><ref id="B95-diagnostics-13-03132"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schowengerdt</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Suyemoto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Main</surname><given-names>F.B.</given-names></name></person-group><article-title>Granulomatous and fibrous mediastinitis. A review and analysis of 180 cases</article-title><source>J. Thorac. Cardiovasc. Surg.</source><year>1969</year><volume>57</volume><fpage>365</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/S0022-5223(19)42725-6</pub-id><pub-id pub-id-type="pmid">5773205</pub-id></element-citation></ref><ref id="B96-diagnostics-13-03132"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seferian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steriade</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ja&#239;s</surname><given-names>X.</given-names></name><name name-style="western"><surname>Planch&#233;</surname><given-names>O.</given-names></name><name name-style="western"><surname>Savale</surname><given-names>L.</given-names></name><name name-style="western"><surname>Parent</surname><given-names>F.</given-names></name><name name-style="western"><surname>Amar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jovan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fadel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sitbon</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Pulmonary Hypertension Complicating Fibrosing Mediastinitis</article-title><source>Medicine</source><year>2015</year><volume>94</volume><fpage>e1800</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000001800</pub-id><pub-id pub-id-type="pmid">26554778</pub-id><pub-id pub-id-type="pmcid">PMC4915879</pub-id></element-citation></ref><ref id="B97-diagnostics-13-03132"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>daSilva-deAbreu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bracamonte-Baran</surname><given-names>W.</given-names></name><name name-style="western"><surname>Condado</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Babaliaros</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tafur-Soto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mandras</surname><given-names>S.A.</given-names></name></person-group><article-title>Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis-Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis</article-title><source>Curr. Probl. Cardiol.</source><year>2021</year><volume>46</volume><fpage>100616</fpage><pub-id pub-id-type="doi">10.1016/j.cpcardiol.2020.100616</pub-id><pub-id pub-id-type="pmid">32532452</pub-id></element-citation></ref><ref id="B98-diagnostics-13-03132"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Interventional therapy in sarcoidosis-associated pulmonary arterial stenosis and pulmonary hypertension</article-title><source>Clin. Respir. J.</source><year>2015</year><volume>11</volume><fpage>906</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1111/crj.12435</pub-id><pub-id pub-id-type="pmid">26666961</pub-id></element-citation></ref><ref id="B99-diagnostics-13-03132"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ogino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shiotsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takumi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hiraoka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Handa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>S.</given-names></name></person-group><article-title>Sarcoidosis complicated with major pulmonary artery obstruction and stenosis</article-title><source>Intern. Med.</source><year>2012</year><volume>51</volume><fpage>2775</fpage><lpage>2780</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.51.7693</pub-id><pub-id pub-id-type="pmid">23037473</pub-id></element-citation></ref><ref id="B100-diagnostics-13-03132"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takemura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saiki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mikami</surname><given-names>R.</given-names></name></person-group><article-title>Pulmonary vascular involvement in sarcoidosis: A report of 40 autopsy cases</article-title><source>Hum. Pathol.</source><year>1992</year><volume>23</volume><fpage>1216</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1016/0046-8177(92)90288-E</pub-id><pub-id pub-id-type="pmid">1427751</pub-id></element-citation></ref><ref id="B101-diagnostics-13-03132"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takemura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oritsu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hiraga</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Omichi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirasawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saiki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mochizuki</surname><given-names>I.</given-names></name></person-group><article-title>Pulmonary vascular involvement in sarcoidosis: Granulomatous angiitis and microangiopathy in transbronchial lung biopsies</article-title><source>Virchows Arch. A Pathol. Anat. Histopathol.</source><year>1991</year><volume>418</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1007/BF01600167</pub-id><pub-id pub-id-type="pmid">1850897</pub-id></element-citation></ref><ref id="B102-diagnostics-13-03132"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Gourin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>H.A.</given-names></name></person-group><article-title>Granulomatous pulmonary angiitis in sarcoidosis</article-title><source>Arch. Pathol. Lab. Med.</source><year>1977</year><volume>101</volume><fpage>170</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">576782</pub-id></element-citation></ref><ref id="B103-diagnostics-13-03132"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hatanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kitazono</surname><given-names>I.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tabata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Higashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yokose</surname><given-names>T.</given-names></name><name name-style="western"><surname>Uekusa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanimoto</surname><given-names>A.</given-names></name></person-group><article-title>Pulmonary infarction caused by sarcoidosis vascular involvement: A case report</article-title><source>Pathol. Int.</source><year>2021</year><volume>71</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1111/pin.13104</pub-id><pub-id pub-id-type="pmid">33902154</pub-id></element-citation></ref><ref id="B104-diagnostics-13-03132"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernaudin</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Le Pavec</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fadel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jeny</surname><given-names>F.</given-names></name><name name-style="western"><surname>Valeyre</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Montpreville</surname><given-names>T.V.</given-names></name></person-group><article-title>Intimal granulomatous angiitis in sarcoid pulmonary vasculitis: Worth remembering</article-title><source>ERJ Open Res.</source><year>2023</year><volume>9</volume><fpage>00549</fpage><lpage>02022</lpage><pub-id pub-id-type="doi">10.1183/23120541.00549-2022</pub-id><pub-id pub-id-type="pmid">37143848</pub-id><pub-id pub-id-type="pmcid">PMC10152265</pub-id></element-citation></ref><ref id="B105-diagnostics-13-03132"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hansell</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>N.K.</given-names></name></person-group><article-title>Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis</article-title><source>Eur. Respir. J.</source><year>2009</year><volume>34</volume><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1183/09031936.00044609</pub-id><pub-id pub-id-type="pmid">19648528</pub-id></element-citation></ref><ref id="B106-diagnostics-13-03132"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffstein</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ranganathan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mullen</surname><given-names>J.B.</given-names></name></person-group><article-title>Sarcoidosis simulating pulmonary veno-occlusive disease</article-title><source>Am. Rev. Respir. Dis.</source><year>1986</year><volume>134</volume><fpage>809</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1164/arrd.1986.134.4.809</pub-id><pub-id pub-id-type="pmid">3767134</pub-id></element-citation></ref><ref id="B107-diagnostics-13-03132"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pour-Ghaz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kayali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abutineh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nayyar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yedlapati</surname><given-names>N.</given-names></name></person-group><article-title>Cardiac Sarcoidosis: Pathophysiology, Diagnosis, and Management</article-title><source>Hearts</source><year>2021</year><volume>2</volume><fpage>234</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.3390/hearts2020019</pub-id></element-citation></ref><ref id="B108-diagnostics-13-03132"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Cawley</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Heitner</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Klem</surname><given-names>I.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jaroudi</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Meine</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>White</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.W.</given-names></name><etal/></person-group><article-title>Detection of myocardial damage in patients with sarcoidosis</article-title><source>Circulation</source><year>2009</year><volume>120</volume><fpage>1969</fpage><lpage>1977</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.851352</pub-id><pub-id pub-id-type="pmid">19884472</pub-id><pub-id pub-id-type="pmcid">PMC2778859</pub-id></element-citation></ref><ref id="B109-diagnostics-13-03132"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapelon-Abric</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sene</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saadoun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cluzel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vignaux</surname><given-names>O.</given-names></name><name name-style="western"><surname>Costedoat-Chalumeau</surname><given-names>N.</given-names></name><name name-style="western"><surname>Piette</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Cacoub</surname><given-names>P.</given-names></name></person-group><article-title>Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors</article-title><source>Arch. Cardiovasc. Dis.</source><year>2017</year><volume>110</volume><fpage>456</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.acvd.2016.12.014</pub-id><pub-id pub-id-type="pmid">28566197</pub-id></element-citation></ref><ref id="B110-diagnostics-13-03132"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>N.</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>P.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garcia-Buitrago</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirsaeidi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>C.</given-names></name></person-group><article-title>Hepatic Sarcoidosis: Natural History and Management Implications</article-title><source>Front. Med.</source><year>2019</year><volume>6</volume><fpage>232</fpage><pub-id pub-id-type="doi">10.3389/fmed.2019.00232</pub-id><pub-id pub-id-type="pmcid">PMC6831521</pub-id><pub-id pub-id-type="pmid">31737633</pub-id></element-citation></ref><ref id="B111-diagnostics-13-03132"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edoute</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical manifestations of sarcoid liver disease</article-title><source>J. Gastroenterol. Hepatol.</source><year>2004</year><volume>19</volume><fpage>732</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2003.03335.x</pub-id><pub-id pub-id-type="pmid">15209617</pub-id></element-citation></ref><ref id="B112-diagnostics-13-03132"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calender</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weichhart</surname><given-names>T.</given-names></name><name name-style="western"><surname>Valeyre</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>Y.</given-names></name></person-group><article-title>Current Insights in Genetics of Sarcoidosis: Functional and Clinical Impacts</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>2633</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9082633</pub-id><pub-id pub-id-type="pmid">32823753</pub-id><pub-id pub-id-type="pmcid">PMC7465171</pub-id></element-citation></ref><ref id="B113-diagnostics-13-03132"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cocconcelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bernardinello</surname><given-names>N.</given-names></name><name name-style="western"><surname>Castelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Petrarulo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bellani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saetta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spagnolo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Balestro</surname><given-names>E.</given-names></name></person-group><article-title>Molecular Mechanism in the Development of Pulmonary Fibrosis in Patients with Sarcoidosis</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>10767</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241310767</pub-id><pub-id pub-id-type="pmid">37445947</pub-id><pub-id pub-id-type="pmcid">PMC10341418</pub-id></element-citation></ref><ref id="B114-diagnostics-13-03132"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobiecka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lewandowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kober</surname><given-names>J.</given-names></name><name name-style="western"><surname>Franczuk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Skoczylas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tomkowski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ku&#347;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Szturmowicz</surname><given-names>M.</given-names></name></person-group><article-title>Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?</article-title><source>Lung</source><year>2020</year><volume>198</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1007/s00408-020-00346-1</pub-id><pub-id pub-id-type="pmid">32206858</pub-id><pub-id pub-id-type="pmcid">PMC7242254</pub-id></element-citation></ref><ref id="B115-diagnostics-13-03132"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crouser</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Bonham</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Morgenthau</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Abston</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Blankstein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.S.</given-names></name><etal/></person-group><article-title>Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2020</year><volume>201</volume><fpage>e26</fpage><lpage>e51</lpage><pub-id pub-id-type="doi">10.1164/rccm.202002-0251ST</pub-id><pub-id pub-id-type="pmid">32293205</pub-id><pub-id pub-id-type="pmcid">PMC7159433</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="diagnostics-13-03132-t001" orientation="portrait"><object-id pub-id-type="pii">diagnostics-13-03132-t001_Table 1</object-id><label>Table 1</label><caption><p>Haemodynamic categories of pulmonary hypertension [<xref rid="B1-diagnostics-13-03132" ref-type="bibr">1</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PH Category</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Definition</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pre-capillary PH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mPAP &gt; 20 mmHg, PAWP &#8804; 15 mmHg, PVR &gt; 2 WU</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">isolated post-capillary PH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mPAP &gt; 20 mmHg, PAWP &gt; 15 mmHg, PVR &#8804; 2 WU</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">combined pre- and post-capillary PH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mPAP &gt; 20 mmHg, PAWP &gt; 15 mmHg, PVR &gt; 2 WU</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">unclassified PH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mPAP &gt; 20 mmHg, PAWP &#8804; 15 mmHg, PVR &#8804; 2 WU</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">exercise PH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mPAP/CO slope between rest and exercise &gt; 3 mmHg/L/min</td></tr></tbody></table><table-wrap-foot><fn><p>PH&#8212;pulmonary hypertension, mPAP&#8212;mean pulmonary arterial pressure, PAWP&#8212;pulmonary arterial wedge pressure, PVR&#8212;pulmonary vascular resistance, WU&#8212;Wood units, CO&#8212;cardiac output.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="diagnostics-13-03132-t002" orientation="portrait"><object-id pub-id-type="pii">diagnostics-13-03132-t002_Table 2</object-id><label>Table 2</label><caption><p>Stages of intrathoracic sarcoidosis [<xref rid="B33-diagnostics-13-03132" ref-type="bibr">33</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Features</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no visible intrathoracic findings</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">enlarged hilar lymph nodes only</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">enlarged lymph nodes and parenchymal infiltrates</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">diffuse parenchymal infiltrates without lymphadenopathy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">lung fibrosis</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>